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 The complex pathobiologic mechanisms of emphysema are not fully understood, 
leaving this deadly disease without effective pharmacotherapy for a cure.  This project 
hypothesized that the sulfated dehydropolymer of caffeic acid (CDSO3) exhibits Fe2+ 
chelation-based hypoxia inducible factor-1 (HIF-1 up-regulatory protective activities 
against in vitro emphysematous cell death and for in vivo reversal of emphysema 
induced with SU5416, a vascular endothelial growth factor blocker.   
 Using in vitro chromogenic competitive inhibition assays, CDSO3 was shown to 
chelate Fe2+ (IC50 of 23 µM), but not Fe3+ ions.  The trypan blue exclusion and lactate 
dehydrogenase assays were then employed to examine the cytoprotective activities of 
CDSO3 against inflammatory, oxidative, elastolytic, and apoptotic cell death using 
alveolar macrophages, epithelial and endothelial cells.  CDSO3 at 10 µM produced 
significant protective activities against these emphysematous cell deaths by 50-154 %.  
These protective effects were opposed by the addition of the HIF-1 inhibitors, 
CAY10585 and echinomycin, and excess Fe2+, but not Fe3+, ions. 
 Emphysema was then induced in rats following a subcutaneous injection of 
SU5416 at 20 mg/kg, after which CDSO3 at 60 µg/kg was administered to the lungs 3 
times/week for two weeks.  Treadmill exercise endurance (EE) was measured to assess 
the functional impairment, while lung tissues were removed for morphological 
assessments of alveolar airspace enlargement (MLI) and destruction (DI), as well as to 
measure protein levels using Western blot.  SU5416 significantly impaired EE, MLI, and 
DI by 81 %, 47 %, and 5-fold, compared to the healthy animals, and these were 
significantly reversed by CDSO3 by 66, 74, and 87 %.  CDSO3 treatment did not 
change the lung cytoplasmic expression of histone deacetylase 2 (HDAC2), HIF-1, or 
a pro-apoptotic marker, BAX.  However, induction with SU5416 significantly reduced 
VEGF expression by 52 % and increased cleaved caspase-3 expression by 1.5-fold, 
compared to the healthy animals, while CDSO3 normalized the expressions of both 
proteins in these emphysematous animals.  However, when CDSO3 was pre-mixed with 
excess Fe2+, the reversal activities of CDSO3 were diminished.  In conclusion, this study 
has demonstrated the Fe2+ chelation-based HIF-1 up-regulatory dependent in vitro and 
















1.1 BURDEN AND OUTLOOK 
 
 Pulmonary emphysema is a life-threatening lung disease that most often 
develops in chronic cigarette smokers between the ages of 45 and 60 as one of the 
major manifestations of chronic obstructive pulmonary disease (COPD) [Taraseviciene-
Stewart et al., 2008; Koblizek et al., 2016].  Recent studies have estimated the COPD 
prevalence to be 5-25 % [Rycroft et al., 2012; Buist et al., 2007], while approximately 
50.0-98.3% of patients are under-diagnosed worldwide [Koblizek et al., 2016].  Clinical 
symptoms include chronic cough, excessive sputum production, and dyspnea, leading 
to physical and functional disability, and eventually death [Andersson et al., 2015; 
Koblizek et al., 2016; Celli et al., 2004; Stridsman et al., 2014; Karpman et al., 2014; 
Tuder, 2008].  COPD is currently the third leading cause of death in the United States, 
affecting 13 million people, and costing nearly $50 billion annually [Tuder et al., 2012; 
Ford et al., 2015; NHLBI 2012].  Similarly, the World Health Organization (WHO) has 
predicted a rapidly increasing prevalence of this disease worldwide, so that it would 
become the third leading cause of worldwide mortality and the fifth leading cause of 
morbidity by 2020, imposing a burden of $47 trillion by 2030 [Tuder et al., 2012; 
 3 
Taraseviciene-Stewart et al., 2008; Murray et al., 1996; Sullivan et al., 2000].  
Therefore, there is clearly an urgent need to discover and develop novel drug molecules 
capable of reversing emphysema for cure in order to address this global epidemic. 
 
 
1.2 RISK FACTORS 
 
 Chronic cigarette smoking is the undisputed leading cause of emphysema, 
although other factors, such as exposure to household indoor biomass fumes, 
environmental and occupational exposure to dust, chemicals, and asbestos, as well as 
respiratory infections and aging, all contribute to the overall epidemiology of 
COPD/emphysema [Yoshida et al., 2007; Stockley et al., 2009; Taraseviciene-Stewart 
et al., 2008; Koblizek et al., 2016].  Chronic cigarette smoking is responsible for 80-90 
% of COPD cases in the United States; hence, quitting smoking would inarguably be the 
best way to prevent emphysema [Yoshida et al., 2007].  However, the success rate for 
smoking cessation is as low as 7-10 % [Messer et al., 2008], and it has also been 
reported that slow and progressive destruction of the lung parenchyma still occurs even 
after smoking cessation, for which reasons remain unclear [Yoshida et al., 2007; Hodge 
2005, Taraseviciene-Stewart et al., 2008].  Furthermore, smokers show considerable 
variation in their risk of developing airflow destruction, which suggests that there may be 
genetic factors that contribute to the development of this disease [Sandford et al., 2002].  
To date, however, the only proven genetic risk factor for COPD thus far is severe 
deficiency of 1-antitrypsin (AAT), which accounts for only 1-2 % of patients with COPD 
[Hersch et al. 2008; Hutchison et al., 1971].  Among many candidate genes, 
 4 
polymorphic variations in surfactant protein B, mannose-binding lectin, SERPINE2 
gene, and matrix metalloproteinase-9 promoter have all been associated with 
exacerbations of COPD, yet their validation has still to be completed [Hansel et al., 
2009; Foreman et al., 2008; Yang et al., 2003; Demeo et al., 2006; Ito et al., 2005(b)].  
Hence, at present, the pathobiologic mechanisms of emphysema still remain largely 
unknown, such that clarification of these pathobiological processes is critical for the 




 While it is characterized by the destruction and loss of the alveolar septa, 
resulting in abnormal and irreversible enlargement of the airspaces (Figure 1.1), the 
cellular and molecular mechanisms of emphysema are complex and not fully 
understood even today [Snider et al., 1985; Fisher et al., 2011; Voelkel et al., 2011].  As 
a result, there have been no pharmacologic cure for emphysema, and the present 
treatment options are limited to non-pharmacological and pharmacological therapies for 
symptomatic relief and management of complications, to improve quality-of-life (QOL) in 




Figure 1.1:  Normal versus emphysematous lung alveoli.  The image has been taken 
from WebMD [http://www.webmd.com/lung/emphysema].  
 
  
 1.3.1 Non-pharmacological therapy 
 
 Smoking cessation has been attempted together with nicotine replacement 
therapy (NRT) such as sustained nicotine patches, and medications approved by the 
Food and Drug Administration (FDA) for smoking cessation, i.e., buproprion (Zyban), 
varenicline, and cytosine [Piper et al., 2009; Watsky et al., 2006].  While the success 
rates for NRT and pharmacotherapy alone are similar, their concomitant use has 
yielded higher success rates as high as 33-37% [Mulhall et al., 2016].  The newest 
cessation tool is electronic cigarette, a device designed to emit vaporized nicotine 
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without noxious substances contained in real cigarettes.  Although a Cochrane review of 
e-cigarettes concluded that, while they are effective for cessation and their use over 2 
years resulted in no significant adverse effects, additional studies and regulations are 
necessary before their widespread adoption [McRobbie et al., 2014; McCauley et al., 
2012].  By contrast, pulmonary rehabilitation programs (PRP) can recondition patient’s 
non-pulmonary organs to improve exercise tolerance, exertional dyspnea, walk 
distance, and health-related QOL; however, no study has been shown to improve 
pulmonary function or mortality [Mulhall et al., 2016].  Long-term oxygen therapy has 
been used to palliate dyspnea and improve mortality, and non-invasive positive 
pressure ventilation has also been used to treat acute and chronic respiratory failure 
[Mullhall et al., 2016].  More invasive procedures include lung volume reduction surgery 
and lung transplantation for end-stage lung disease.  However, these non-
pharmacological options are expensive, invasive, and produce inconsistent results. 
  
 1.3.2 Pharmacological therapy  
 
 Currently, pharmacological therapy for COPD/emphysema is available only to 
reduce its symptoms, reduce the frequency and severity of exacerbations, and improve 
health status and exercise tolerance.  Bronchodilators are the mainstay of 
COPD/emphysema management and are recommended by national and international 
guidelines as first-line therapy in symptomatic patients who demonstrate airflow 
limitation [Hanania et al., 2007].  Three classes of bronchodilators – 2-adrenoreceptor 
agonists, anticholinergics, and methylxanthines – are currently in use for 
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COPD/emphysema as summarized in Table 1.1.  Inhaled short-acting bronchodilators 
are recommended for rescue of symptoms in mild disease due to their rapid onset of 
action, and increased mucociliary clearance [Hanania et al., 2007; GOLD 2016]. Inhaled 
long-acting bronchodilators are the first-line agents for maintenance of daily symptoms 
in moderate to severe COPD/emphysema [Hanania et al., 2007; GOLD 2016].  When 
symptoms are not sufficiently controlled with one bronchodilator, it is recommended to 
combine bronchodilators of different classes [GOLD 2016].  Meanwhile, inhaled 
corticosteroids (ICS) when used regularly, improve symptoms, lung function and QOL, 
and reduces the frequency of exacerbations; however, withdrawal from ICS treatment 
has been shown to lead to exacerbations in some patients [GOLD 2016].  Furthermore, 
ICS are associated with higher incidences of oral candidiasis, skin bruising, increased 
risk of reduced bone density and fractures [GOLD 2016].  It should be emphasized that 
these bronchodilators and ICS only reduce the frequency and severity of exacerbations. 
To date, none of the existing medications has been shown to modify the long-term 























2-agonist Albuterol (salbutamol)  
(MDI, DPI, NS, PO) 
Salmeterol (MDI, DPI) 
Formoterol (MDI, DPI, NS) 
Levalbuterol (MDI, NS) Arformoterol (NS) 




Terbutaline (DPI, PO)  
Anticholinergic Ipratropium bromide  
(MDI, NS) 
Tiotropium bromide (DPI) 
Umeclidinium (DPI) 
Oxitropium bromide  
(MDI, NS) 
Aclidinium bromide (DPI) 
Glycopyrronium bromide (DPI) 




Fenoterol/Ipratropium (SMI) Formoterol/Aclidinium (DPI) 
 Indacaterol/glycopyrronium 
(DPI) 
 Oladaterol/tiotropium (SMI) 
 Vilanterol/umeclidinium (DPI) 
Methylxanthine Theophylline (PO) 
 Aminophylline (PO) 
 CORTICOSTEROIDS 
 Inhaled Systemic 
Beclomethasone  
(MDI, DPI, NS) 
Prednisone (PO) 
Methyl-prednisolone (PO) 
Budesonide (DPI, NS)  
Fluticasone (MDI, DPI)  
Combination Formoterol/beclometason (MDI, DPI) 
 Formoterol/budesonide (MDI, DPI) 
 Formoterol/mometasone (MDI) 
 Salmeterol/Fluticasone (DPI) 
 Vilanterol/Fluticasone furoate (DPI) 
 PHOSPHODIESTERASE-4 INHIBITORS 
 Roflumilast (PO) 
DPI = dry powder inhaler; MDI =metered dose inhaler; SMI = soft mist inhaler; NS = 







 The lack of effective therapy to prevent and/or treat emphysema is largely due to 
its enigmatic multi-faceted pathobiologic mechanisms that remain not fully understood 
even today.  Several hypotheses have been proposed to explain the pathobiologic 
mechanisms of emphysema, among which persistent inflammation, oxidative stress, 
and protease-antiprotease imbalance have been considered to be key components 
[Suki et al., 2003; Barnes 2009; Stockley et al., 2009; Voelkel et al., 2011; Fischer et al., 
2011].  However, treatment strategies that target one or more of these mechanisms 
have been unsuccessful to reverse emphysematous lung damages toward a cure.  
Thus, a new pathobiologic concept has been recently proposed, based on an imbalance 
of increased lung cell death and decreased cell proliferation, due to the failure of the 
homeostatic lung structure maintenance program [Taraseviciene-Stewart et al., 2008; 
Mizuno et al., 2011; Lee et al., 2012].  In line with this concept, lungs from patients with 
COPD have been shown to possess apoptotic cells in greater numbers than control 
lungs or those from smokers without COPD [Demedts et al., 2006; Imai et al., 2005; 
Kasahara et al., 2000; Yokohori et al., 2004].  This apoptosis has been shown to persist 
in patients with COPD long after smoking cessation, suggesting that cigarette smoke 
itself is not the sole agent causing the apoptosis [Henson et al., 2006; Hodge et al., 
2005].  These, in addition to other various risks for smokers to develop 
COPD/emphysema, have shifted research to investigate epigenetic modifications in the 
lungs of COPD/emphysema patients as a cause for this imbalance.  
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 The failure of the homeostatic lung structure maintenance program has been 
now attributed to the epigenetically reduced expression of one of the essential lung 
structure maintenance factors, vascular endothelial growth factor (VEGF), and one of its 
upstream transcription factors, hypoxia-inducible factor-1 (HIF-1), as seen in patients 
with COPD/emphysema [Yasuo et al., 2011; Kasahara et al., 2000; Tuder et al., 2008; 
Kasahara et al., 2001].  Because VEGF stimulates endothelial cell growth and its 
removal causes endothelial cell apoptosis, VEGF is considered to be an essential 
element required for the survival of endothelial cells [Neufeld et. al, 1999; Gerber et al., 
1998a; Gerber et al., 1998b].  Indeed, reduced expression of VEGF and HIF-1 has 
been shown to cause apoptosis and emphysema at cell and animal levels [Yasuo et al., 
2011; Lee et al., 2012; Kasahara et al., 2000].   It was therefore hypothesized that this 
“HIF-1a/VEGF deficiency” is responsible for the failure of the homeostatic lung structure 
maintenance program, such that recovery of lung’s HIF-1 and VEGF levels may be a 
new strategy to reverse the imbalance of cell death and cell proliferation in emphysema.  
 By now, it has been shown that this reduced HIF-1/VEGF expression is likely 
caused by up-stream inhibition of histone deacetylase (HDAC) [Ellis et al., 2009; Mie 
Lee et al., 2003; Qian et al., 2006].  Cigarette smoke exposure has been shown to affect 
chromatin remodeling [Yang et al., 2006], and decreased expression of HDAC, 
specifically HDAC2, was seen in the lungs from patients with COPD [Ito et al., 2005a; 
Mizuno et al., 2011], correlated with increased expression of inflammatory genes 
[Barnes 2009; Ito et al., 2001].  In addition, it was reported that HDAC inhibition 
increased binding of nuclear factor kappa-light-chain enhancer of activated B cells (NF-
B) to hydrogen peroxide (H2O2)-challenged alveolar cells [Rahman 2002], and that 
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reduced HDAC2 expression resulted from oxidative stress [Ito et al., 2004], with 
reasonable correlations of HDAC inhibition with oxidative stress and inflammation.  
These relevant findings have led this research to hypothesize that, while originating 
from the triple causative features of elastolysis, oxidative stress, and inflammation, the 
pathobiological mechanism for emphysema involves epigenetic modifications to cause 
“HIF-1/VEGF deficiency”, leading to increased cell death and emphysema, as shown 
































1.5 HYPOXIA-INDUCIBLE FACTOR-1  
 
 HIF-1 is an oxygen sensitive, ubiquitous transcription factor, which controls 
many downstream genes for various functions, including cell death and cell proliferation.   
As described in Figure 1.3, under normoxic conditions and in the presence of Fe2+ and 
2-oxoglutarate, the conserved proline residues (Pro-402 and Pro-564) of HIF-1 within 
the oxygen-dependent degradation domain (ODD) are hydroxylated by prolyl 
hydroxylase (PHD) domain proteins [Ivan et al., 2001; Jaakkola et al., 2001; Masson et 
al., 2001; Fan et al., 2014].  The hydroxylated HIF-1then interacts with the -domain 
of von Hippel-Lindau tumor suppressor protein (VHL) and is subsequently ubiquitylated 
by the VHL-E3 ligase complex, thereby marking HIF-1 for degradation by the 26S 
proteasome [Maxwell et al., 1999; Ohh et al., 2000].  In contrast, under hypoxic 
conditions or in the absence of the essential co-factors, Fe2+ and 2-oxoglutarate, the 
catalytic activity of PHDs is inhibited, and thus, HIF-1 is stabilized and translocates into 
the nucleus where it dimerizes with the HIF-1 subunit, which is constitutively 
expressed in the nucleus.  The HIF1 dimer then interacts with the transcriptional co-
activators p300/Creb-binding protein (CBP) and forms a transcriptional complex [Sang 
et al., 2002; Arany et al., 1996].  This transcriptional complex binds to hypoxia response 
elements (HREs) of hypoxia-responsive target genes, thereby promoting the expression 
of genes that regulate angiogenesis and cell survival, such as VEGF.  Therefore, 
pharmacologic inhibition of HIF-PHD by depleting the essential Fe2+ could be a means 
of stabilizing HIF-1, and thereby overcoming the pathobiologic critical ‘HIF-1 
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deficiency’ in emphysema, as increasing angiogenesis and inhibiting cell death [Sears 






















































1.6 SULFATED DEHYDROPOLYMER OF CAFFEIC ACID (CDSO3) 
 
 Recently, dehydropolymers (DHPs) of 4-hydroxy cinnamic acids were discovered 
as a novel class of anti-coagulants via direct inhibition of thrombin and factor Xa 
[Monien et al., 2006].  Among them, unsulfated and sulfated caffeic acid (CA) oligomers 
were chemo-enzymatically synthesized, as described in Figure 1.4 [Monien et al., 
2006].  CA monomers were coupled via horseradish peroxidase (HRP)-catalyzed 
oxidation in the presence of H2O2, generating radical intermediates, I1 and I2.  These 
radical intermediates were coupled with CA monomers to give -O-4- and -5-linked 
dimeric units, which then underwent further chain extensions with radicals to result in 4-
15 units oligomerization to CA-based dehydropolymers (DHPs).  These unsulfated 
DHPs of CA were then reacted with triethylamine-sulfure trioxide (Et3N/SO3) complex, 
yielding sulfated DHP of CA, or CDSO3.  The average molecular weight was 
determined by size exclusion chromatography using their acetylated derivatives, 
resulting in an average of 3320 Da [Henry et al., 2007].  The elemental analysis 
revealed that sulfation was added as 0.30-0.40 moles per monomer unit of CDSO3 
[Monien et al., 2006].  The prothrombin and activate partial thromboplastin (PT and 
APTT) were measured with citrated human plasma at six to eight concentrations of CD 
and CDSO3.  In these assays, the anticoagulant activity was defined as the 
concentration of the DHPs needed for doubling the normal plasma clotting time [Monien 
et al., 2006].  To assess the effect of CD and CDSO3 on the proteolytic activities of 
coagulation proteinases, factor Xa and thrombin, the residual enzymatic activity of the 
two enzymes following incubation for a defined time period with varying concentrations 
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of DHPs in the presence and absence of antithrombin was measured [Monien et al., 
2006].  The proteinase activity was determined under pseudo-first order conditions in a 
spectrophotometric assay using chromogenic substrates Sepctrozyme fXa and TH for 
factor Xa and thrombin, respectively.  As the concentration of DHP increases, the 
residual proteinase activity decreases in a sigmoidal manner, which can be fit to a 
standard dose-dependence equation to derive the IC50 values.  Their in vitro 
prothrombin and activated partial thromboplastin times (PT and APTT, respectively), 
and inhibitory binding activities to factor Xa and thrombin, suggested that sulfation 
substantially potentiated the activities for CDSO3, compared to the unsulfated DHP, or 
CD.  These physiochemical and anti-coagulant activities of CD and CDSO3 are 






Figure 1.4:  Synthetic scheme of the sulfated dehyodropolymer of caffeic acid (CDSO3) 
[Monien et al., 2006] 
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Table 1.2: Average molecular weight, sulfate density, and in vitro anti-coagulation 
activities of the unsulfated and sulfated dehydropolymers (DHPs) of caffeic acid, CD 






IC503 Clotting assay4 
Factor 
Xa 




CD 2,800 NA 0.14 0.07 98.1±0.7 24.9±2.3 
CDSO3 3,320 0.40 0.03 0.02 42.1±0.3 13.0±5.0 
1Weight-averaged molecular weight 
2Averaged molar number of sulfates per monomeric unit, derived from elemental 
composition analysis and averaged oligomer size   
3The half-maximal inhibitory concentration (IC50) obtained from chromogenic substrate 
hydrolysis assays for each enzyme.  
4The PT and APTT values were derived from in vitro human plasma experiments using 
thromboplastin or ellagic acid, respectively, as a clotting initiator
 20 
 
1.7 CDSO3 FOR EMPHYSEMA 
 
 Many molecules have been examined for the treatment of emphysema in the 
past few decades.  Retinoic acid was shown to inhibit elastase-induced injury in lung 
epithelial cells [Nakajoh et al., 2003].  Molecules exerting dual inhibitory action, i.e., anti-
inflammatory and anti-oxidative activities, such as curcumin and resveratrol, 
demonstrated improvements in the triple-threat pathogenesis [Biswas et al., 2005; 
Epstein et al., 2010; Rahman et al., 2006].  Likewise, novel coumarinic derivatives have 
been shown to be anti-inflammatory and anti-elastase [Bissonnette et al., 2009].  
However, no molecule has been discovered to exhibit triple-inhibitory action against 
elastase, oxidation, and inflammation.   
 It was intriguing that the complex pathogenesis of emphysema that involves 
oxidative stress, inflammation, and elastolysis somewhat resembles that seen in blood 
coagulation.  Chronic cigarette smokers have increased blood viscosity due to higher 
levels of thrombin and fibrinogen and lower levels of anti-factor Xa, all attributed to 
systemic oxidative stress [Yanbaeva et al., 2007; Hioki et al., 2001; Wannamethee et 
al., 2005].  Therefore, given CDSO3 as a potent inhibitor of blood serine proteases, e.g., 
factor Xa and thrombin (Table 1.2), it was hypothesized that CDSO3 could also inhibit 
the triple-threat pathogenesis of inflammation, elastolysis, and oxidation in emphysema.  
Table 1.3 summarizes the in vitro triple inhibitory activities of CDSO3 along with those 
for the monomer CA and unsulfated oligomer, CD [Saluja et al., 2013].  CDSO3 was 
shown to be the most potent, suggesting that oligomerization and sulfation play key 
roles in their triple inhibitory activities.   
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 Accordingly, the in vivo therapeutic efficacy, duration and mode of actions, and 
the effective route were further tested for CDSO3 in the human sputum elastase and 
cigarette smoke extract (HSE/CSE) rat model of pulmonary emphysema.   CDSO3 was 
shown to attenuate the development of HSE/CSE-induced emphysema in rats following 
pulmonary administration, with a dose of 100 µg/kg in both preventive and interventional 
manners [Saluja et al., 2014].  Preventative treatment showed significant (53-89 %) 
attenuation in bronchoalveolar lavage fluid (BALF) elastase, lung tissue reduced 
glutahione (rGSH), and BALF tumor necrosis factor-alpha (TNF , airway luminal 
leukocyte infiltration, exercise endurance, and airspace enlargement [Saluja et al., 
2014].  Likewise, interventional treatment also attenuated the lung luminal elastolytic 
and inflammatory inductions, neutrophil infiltration, impaired exercise endurance, and 
airspace enlargement by 43-82 % [Saluja et al., 2014].  By contrast, systemic 
subcutaneous injection of CDSO3 was ineffective, in turn suggesting a need for local 
pulmonary delivery [Saluja et al., 2014].  Hence, CDSO3 has been discovered as one of 
the first drug entities capable of triple-inhibitory activities in emphysema in vitro as well 
as in vivo.   
 Recently, Sakagami et al. [2014] attempted pulmonary delivery of CDSO3 to 
repair lung damages in emphysematous lungs in the CSE-induced rat model of 
emphysema.  The pathobiologically impaired “HIF-1/VEGF deficiency” hypothesized in 
this research was shown in this model.  Moreover, two week pulmonary administration 
of CDSO3 at 60 µg/kg significantly improved impaired exercise endurance by 50-70 % 
and restored increased airspace size by 42-73 %.  When CDSO3 was pre-mixed with 
excess Fe2+ and a HIF-1 inhibitor, 2-methoxyestradiol, the reversal activities of 
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CDSO3 were opposed, supporting CDSO3’s Fe2+ chelation-based HIF1-mediated 
mechanism in this CSE-induced emphysema model.  However, lung cell-specific repair 
and its mechanism have yet to be proven, while the reversal efficacy in differently-
induced emphysema remain unknown.  The latter could especially be critical, as the 
CSE-induced emphysema used in previous study [Sakagami 2014] has not yet been 
widely accepted as an experimental emphysema model.  Furthermore, although CSE-
induced emphysema causes necrosis, the VEGF receptor blocker model of emphysema 
induced with SU5416 has been shown to cause apoptosis and emphysema [Kasahara 

















Table 1.3:  The half-maximal inhibitory concentration (IC50) and the Hill slope (HS) for 
CA, CD, and CDSO3 in the in vitro ant-elastase, anti-oxidative, and anti-inflammatory 
activity assessments [Saluja et al., 2013] 
 Anti-elastase1 Anti-oxidation2 Anti-inflammation3  
IC50 [µM] HS IC50 [µM] HS IC50 [ µM] 
CA NA NA 16.82±1.16 2.9±0.5 >100 
CD 2.82±0.20 1.1±0.1 6.15±0.33 3.3±0.6 ~50 
CDSO3 0.43±0.04 1.6±0.2 3.52±0.14 3.7±0.5 ~10 
1Anti-human neutrophil elastase (HNE) activity derived from the non-linear regression 
curve-fitting to the p-nitroanalide (pNA) generation vs. concentration profiles.  Values 
are shown as mean±SD 
2Anti-chemical oxidative activity derived from the non-linear regression curve-fitting to 
the ABTS•+ generation vs. concentration profiles.  Values are shown as mean±SD 

















 The goal of this dissertation project was to further demonstrate the therapeutic 
potential CDSO3 as a novel macromolecular drug entity for pulmonary delivery in the 
treatment of emphysema and COPD.  It was hypothesized that CDSO3 was capable of 
repairing lung damages and reversing emphysema.  Specifically, this dissertation 
project was aimed to demonstrate 1) ferrous (Fe2+) and ferric (Fe3+) ion chelation 
activities of CDSO3 and their batch-to-batch differences, 2) the Fe2+- and HIF-1-
dependent in vitro cytoprotective activity of CDSO3, and 3) the Fe - and HIF-1-
dependent lung repairing activities in an in vivo rat model of established pulmonary 
emphysema.  Hence, the project is designed to test the following 3 hypotheses:  
1. Despite differences in the elemental and physiochemical properties, two different 
synthetic batches of CDSO3 exert comparable, but potent Fe2+ chelating activity, 
and cytoprotective activity. 
2. CDSO3 exerts potent Fe2+- and HIF-1-dependent in vitro cytoprotective 
activities against differently induced emphysematous cell death in alveolar 
macrophages, epithelial cells, and lung vascular endothelial cells. 
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3. Pulmonary delivery of CDSO3 reverses the functional and morphological 
impairments and normalize/stimulate HIF-1 and HIF-regulating proteins in an in 
vivo apoptotic rat model of established emphysema induced by VEGF receptor 
blockade  
 
 In Chapter 3, the ferrous and ferric ion chelating activities of CDSO3 were 
assessed using the in vitro chromogenic ferrozine and sulfosalicylic acid chelation-
based competitive inhibition assays, respectively.  Subsequently, the in vitro 
cytoprotective activities of CDSO3 and known iron chelators (DFO and EDTA) against 
differently induced emphysematous cell death in three different lung cell lines were 
assessed in Chapter 4.  Cell death was measured using the trypan blue exclusion (TBE) 
and lactate dehydrogenase (LDH) assays, and the effects of HIF-1 inhibitors and 
excess Fe2+ or Fe3+ were tested to clarify the Fe2+ and HIF-1-dependent mechanisms 
for CDSO3’s cytoprotective actions.  This led to Chapter 5, where the lung repairing 
activities of CDSO3 was assessed in the VEGF receptor blockade model of established 
emphysema in rats.  Finally, Chapter 6 will summarize all the findings in this dissertation 






























 CDSO3 (Figure 3.1) has been chemo-enzymatically synthesized from caffeic 
acid (CA) monomers via a two-step method, oligomerization followed by sulfation, as 
described in Chapter 1.  It was in 2006 that this CDSO3 synthesis was first published, 
and thereby CDSO3 was characterized as a dehydropolymer composed of 4-15 units of 
CA-based monomers with an average of 0.4 sulfates per monomer and a 
heterogeneous mixture of --4 and -5 linkages; its averaged weight-based molecular 
weight was reported to be 3,320 Da [Monien et al., 2006; Henry et al., 2007].  Hence, 
CDSO3 was not a single chemical entity and rather a mixture of polymers with varying 
degrees of oligomerization and sulfation.    
In this dissertation work, two batches of CDSO3, i.e., CDSO3BH and CDSO3MT, 
prepared in the Desai laboratory, were used [Monien et al., 2006; Thompson, 2015].  
The samples were sent to Atlantic Microlab, Inc. (Norcross, GA) to be analyzed for their 
elemental composition.  It is important to note that the nitrogen content for CDSO3BH 
and the oxygen content for CDSO3MT were not determined.  Their elemental analysis 
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indicated that the ratio of sulfur to carbon (S/C) for CDSO3BH and CDSO3MT were 0.115 
and 0.091, respectively.  Furthermore, the sulfur content for CDSO3BH and CDSO3MT 
were 5.3 % and 3.7 %, respectively.  As summarized in Table 3.1, their elemental 
compositions and distribution coefficients (log D), determined by Monien [2006] and 
Thompson [2015], were also different.  Thus, as an oligomer hypothesized to stabilize 
HIF-1 and elevate VEGF though its ferrous ion (Fe2+) chelating activity, it was crucial 
to first assess Fe2+ chelating activities and ensure their equipotent activities between 
these two batches. Therefore, in this chapter, Fe2+ chelating activities of CDSO3 in the 
two batches were determined using an in vitro chromogenic ferrozine chelation-based 
competitive inhibition assay. In addition, CDSO3MT was further examined for its ferric ion 
(Fe3+) chelating activity by a similar competitive chelation inhibition assay using 
sulfosalicylic acid (SAA) in relation to its use in the in vitro anti-cell death activities 
described in Chapter 4.  The Fe2+ chelating activities of two other known chelators, 
deferoxamine (DFO) and ethylenediaminetetraacetic acid (EDTA) were also assessed.  
It should be noted that batch-to-batch comparison was further extended with respect to 












Figure 3.1:  Chemical structure of CDSO3 (sulfated dehydropolymer of caffeic acid). Its 
primary linkages were reported to be -O-4, -5, and - (shaded).  X1, X2, and X3 are 
substituents at the -position and may be –H, -OH, or –OSO3Na. Z1, Z2, and Z3 may be 














Table 3.1:  Elemental compositional analysis and measured distribution coefficient 
values (log D) for CDSO3 in two different batches [Monien et al., 2006; Thompson, 
2015] 
 Percent (%) elemental compositions1  
Log D 
Carbon Hydrogen Oxygen Nitrogen Sulfur 
CDSO3BH 46.1 4.0 36.7 ND 5.3 0.96±0.09 
CDSO3MT 40.5 3.6 ND 0.55 3.7 0.87±0.09 
1Samples were sent to Atlantic Microlab, Inc. for their elemental composition analysis 
ND: not determined
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3.2 MATERIALS AND METHODS 
  
 3.2.1 Materials 
 
 CDSO3 was prepared in two batches (CDSO3BH and CDSO3MT) in the Desai 
laboratory, as described in Chapter 1.  CDSO3BH was supplied as a 5 mM solution in 
phosphate buffered saline (pH 7.4), while CDSO3MT was supplied as a lyophilized 
powder.  Both batch were aliquoted and stored at -20 oC prior to use; careful precaution 
was taken to prevent the batches from being left at room temperature for > 2 h.  Ferrous 
(Fe2+) sulfate heptahydrate (FeSO4•7H2O) was purchased from Sigma-Aldrich and 
stored at 4 oC, prior to use.  Ferric (Fe3+) chloride (FeCl3; >98.0 % purity) was 
purchased from Spectrum Chemical Mfg. Corp (Gardena, CA) as an anhydrous 
sublimed powder and stored in a desiccator at room temperature prior to use.  
Ethylenediaminetetraacetic acid (EDTA; 99.0 % purity) was purchased from Sigma-
Aldrich as a disodium salt, and stored at room temperature.  Deferoxamine (DFO; ≥92.5 
%purity) was a mesylate salt also obtained from Sigma-Aldrich and stored at -20 oC until 
use.  Ferrozine (3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p’-sulfonic acid monosodium 
salt hydrate) was purchased from Sigma Aldrich, and sulfosalicylic acid (SAA; >99.6% 




 3.2.2 Ferrous ion (Fe2+) chelating activity assessment 
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 The ferrous chelating activity of CDSO3BH and CDSO3MT were assessed using 
the in vitro chromogenic ferrozine chelation-based competitive inhibition assay, adapted 
and modified from Dinis et al. [1994].  A series of concentrations ranging from 0-1000 
µM were tested in triplicates (n=3).  In a 96-well plate, 15 µl of CDSO3 samples and 15 
µl of 0.4 mM FeSO4 were first added to 105 µl deionized, distilled water (DDW), and 
incubated in the dark at room temperature for 10 minutes.  Subsequently, 15 µl of 2 mM 
ferrozine was added, so that competitive chelation was assessed in total 150 µl in each 
well.  In order to accurately measure the absorbance generated only from ferrozine-Fe2+ 
chelation, in an additional reference well (n=1), 15 µl of ddH2O was added in place of 2 
mM ferrozine.  The absorbance was measured at 562 nm using a multi-mode 
microplate reader (Synergy2, Biotek, Winooski, VT) and Gen5 Data Analysis Software 
(Biotek, Winooski, VT).  The absorbance of the reference well was subtracted from that 
of the sample wells and then plotted as a function of concentration in a logarithmic 
scale.  The half-maximal inhibitory concentration (IC50) and Hill slope (HS) values were 
floated for determination from the plots by curve-fitting to the following equation 
(Equation 1) using a non-linear regression analysis software, Scientist (Micromath, St. 
Louis, MO):   
 










Where Y = fraction of Fe2+ bound to ferrozine; Y0 = fraction of Fe2+ bound to ferrozine in 
the absence of the test compound, fixed to 1; Ymin = lowest asymptotic fraction of Fe2+ 
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bound to ferrozine at the highest concentration, fixed to 0; and C = concentration [µM]. 
The “goodness-of-fit” of the curve-fitting was assessed using the Scientist-deriving 
statistical values for the coefficient of determination (COD) and model selection criterion 
(MSC); these were satisfactorily high at ≥0.98 and ≥3.0, respectively.  The Fe2+ 
chelating activities of DFO and EDTA were similarly determined under the same 
experimental procedure and protocol.  
  
 3.2.3 Ferric ion (Fe3+) chelating activity assessment 
 
 The ferric chelating activity of CDSO3MT was assessed using the in vitro 
chromogenic SSA chelation-based competitive inhibition assay, adapted and modified 
from Pozdnyakov et al. [2006].  A series of CDSO3 concentrations ranging from 0-50 
µM were tested in triplicate (n=3).  In a 96-well plate, 15 µl of CDSO3 samples and 15 µl 
of 2 mM FeCl3 were first added to 105 µl deionized, distilled water (DDW), and 
incubated in the dark at room temperature for 10 minutes.  Subsequently, 15 µl of 4 mM 
SAA was added, so that competitive chelation was assessed in total 150 µl in each well. 
In order to accurately measure the absorbance generated only from SAA-Fe3+ 
chelation, in an additional reference well (n=1), 15 µl of ddH2O was added in place of 4 
mM SAA.  The absorbance was measured at 505 nm using Synergy2 (Biotek).  The 
absorbance of the reference well was subtracted from that of the sample wells and then 
plotted as a function of concentration.  
 3.2.4 Data analysis 
 
 33 
 Each data point was expressed as mean ± standard deviation (SD), while the 
mean data were used for curve-fitting. The derived IC50 and HS values were statistically 
compared based on their 95 % confidence interval values (95% CI).  
 
3.3 RESULTS 
   
 3.3.1 Fe2+ chelating activity of CDSO3 in two batches 
 
 Figure 3.2 shows the remaining Fe2+ fraction bound by ferrozine for (a) CDSO3BH 
and (b) CDSO3MT as a function of concentration.  Table 3.2 shows the IC50 and HS 
values derived through curve-fitting along with the “goodness-of-fit” parameters.  The 
IC50 values were 23.3±2.1 (95 % CI: 18.6, 28.0) and 17.0±1.4 (95% CI: 13.6, 20.5) µM, 
respectively, demonstrating that the Fe2+ chelating activity for the two batches of 
CDSO3 significantly different.  However, the HS values were consistent,1.2±0.1 (95 % 
CI: 0.9, 1.4) and 1.4±0.2 (95 % CI: 1.0, 1.8), respectively.  
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(a) 
            
       
(b)                            
  
Figure 3.2:  Remaining Fe2+ fraction bound by ferrozine for (a) CDSO3BH and (b) 
CDSO3MT as a function of concentration; Data are mean±SD from n=3.  The solid lines 







































































Table 3.2: In vitro half-maximal inhibitory concentrations (IC50) and Hill slope (HS) 
values for CDSO3BH and CDSO3MT in the ferrozine chelation inhibition assay, along with 
the COD and MSC values for curve-fitting 
 CDSO3BH CDSO3MT 
IC501 23.3±2.1 (18.6, 28.0) 17.0±1.4 (13.6, 20.5) 
HS2 1.2±0.1 (0.9, 1.4) 1.4±0.2 (1.0, 1.8) 
COD3 0.99 0.99 
MSC4 4.11 4.02 
1Half-maximal inhibitory concentration (µM); derived mean ± SD (95% CI) 
2Hill slope coefficient; derived value ± SD (95% CI) 
3Coefficient of determination; ≥0.98 was considered satisfactory 
















 3.3.2 Fe2+ chelating activity of DFO and EDTA 
 
 Figure 3.3 shows the chelating activity profiles for known ion chelator molecules,  
(a) DFO and (b) EDTA.  The IC50 values were derived to be 31.8±2.1 (95% CI: 27.1, 
36.6) and 24.6±4.8 (95% CI: 13.6, 35.6) µM, respectively, which were slightly less 
potent than that of CDSO3’s.  The HS values for DFO and EDTA were 0.8±0.04 (95 % 
CI: 0.7, 0.9) and 1.0±0.2 (95 % CI: 0.6, 1.5), respectively.  These data demonstrated 
that CDSO3 was as potent as DFO and EDTA in its Fe2+ chelating activity despite being 




















Figure 3.3:  Remaining Fe2+ fraction bound by ferrozine for (a) DFO and (b) EDTA as a 








































































Table 3.3: In vitro half-maximal inhibitory concentrations (IC50) and Hill slope (HS) 
values for DFO and EDTA in the ferrozine chelation inhibition assay, along with the 
COD and MSC for curve-fitting 
 DFO EDTA 
IC501 31.8±2.1 (27.1, 36.6) 24.6±4.8 (13.6, 35.6) 
HS2 0.8±0.04 (0.7, 0.9) 1.0±0.2 (0.6, 1.5) 
COD3 0.99 0.94 
MSC4 4.92 2.48 
1Half-maximal inhibitory concentration (µM); derived mean ± SD (95% CI) 
2Hill slope coefficient; derived value ± SD (95% CI) 
3Coefficient of determination; ≥0.98 was considered satisfactory 
















 3.3.3 Fe3+ chelating activity of CDSO3 
 
 In order to clarify ion selectivity of CDSO3’s activity, such as cytoprotection 
studied in chapter 4, it was of interest to assess its Fe3+ chelation activity.  Figure 3.4 
shows the Fe3+ chelating activity for CDSO3MT up to 50 µM.  CDSO3 appeared to be 
devoid of Fe3+ chelating activities.  This in turn suggests that CDSO3’s chelating 










































































 CDSO3 is a polymer consisting of 4-15 units of caffeic acid (CA) monomers with 
an average molecular weight of 3,320 Da.  Its polydispersity and heterogeneous mixture 
of linkages, stereochemistry, and functional group substitutions result in a large number 
of possible sequences.  Therefore, by nature of its complex structure, there is great 
difficulty in characterizing its structural and physiochemical properties, leading to the 
challenge of reproducibility and minimizing batch-to-batch differences.  Measurements 
of the log D values and elemental analysis of two different batches of CDSO3 
synthesized by two different chemists revealed that they had different physiochemical 
characteristic and elemental composition.  The biggest difference between the batches 
was the sulfur content, with CDSO3BH having 5.3 % whereas CDSO3MT had 3.7 % 
sulfur.  This difference was potentially due to a greater amount of time to undergo de-
sulfation [Thompson, 2015].  It was hypothesized in Chapter 1 that CDSO3’s 
pharmacologic inhibition of HIF-PHD by depleting the essential Fe2+ could be a means 
of stabilizing HIF-1, and thereby overcoming the mechanistically critical ‘HIF-1/VEGF 
deficiency’ in emphysema by increasing angiogenesis and preventing cell death.   
Therefore, the batch-to-batch differences in sulfur content could essentially affect 
CDSO3’s ability to stabilize HIF-1/VEGF and prevent cell death because sulfate 
groups significantly contribute to ferrous ion chelating capacity.  In fact, their derived 
IC50 values were different: 23.3±2.1 (95 % CI: 18.6, 28.0) and 17.0±1.4 (95% CI: 13.6, 
20.5) µM, respectively.  These data suggest that 3.5 % difference in sulfur content 
between these batches do significantly affect the ferrous chelating activity.  Meanwhile, 
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the ferrous ion (Fe2+) chelation activity of CDSO3 was found to be comparable to and 
otherwise, slightly more potent than those of the known chelators, DFO and EDTA (IC50 
values: 31.8±2.1 (95% CI: 27.1, 36.6) and 24.6±4.8 (95% CI: 13.6, 35.6) µM, 
respectively).  Even so, the HS values for CDSO3BH, CDSO3MT, DFO, and EDTA are all 
approximately 1.  CDSO3 appeared to be devoid of ferric ion (Fe3+) chelation activity up 
to 50 µM.  However, the development of a more sensitive assay is necessary to confirm 
these findings.  This presumably suggests that CDSO3’s chelating activities are 




 The complex nature of CDSO3’s chemical structure raises a concern about 
reproducibility and batch-to-batch variance, as potentially causing significant changes in 
its ferrous chelating activity.  However, it was found that the variability in its elemental 
composition and physiochemical properties had only small effects on in vitro ferrous 
chelating activity.  This assures that different batches of CDSO3 will produce relatively 
consistent results, and data from different batches can be treated collectively.  
Furthermore, the ferrous chelating activity of DFO and EDTA were also found to be 
similar to that of CDSO3, with DFO being the least potent.  Although CDSO3 was 
shown to exhibit in vitro ferrous ion (Fe2+) chelation activity with an IC50 of about 17-23 
µM, it does not seem to have ferric ion (Fe3+) chelation activity.  These findings will 
enable further investigation into CDSO3’s Fe2+ chelation-dependent mechanism of its 




















 A new pathobiologic concept of emphysema has been recently proposed, based 
on an imbalance of increased lung cell death and impaired cell proliferation, caused by 
“HIF-1/VEGF deficiency”.  HIF-1is a transcription factor which controls many 
downstream genes for various functions, including cell death and cell proliferation, yet 
its levels are primarily regulated by Fe2+-dependent catalyzing enzymes (HIF-PHDs) for 
degradation.  Therefore, reversal of the “HIF-1/VEGF deficiency” via Fe2+ chelation 
has been proposed as a novel lung repairing strategy in emphysema.  In Chapter 3, our 
non-peptidic, relatively lipophilic CDSO3 was shown to potently chelate Fe2+, exerting 
23 µM of IC50 value in the ferrozine assay.  Hence, this chapter was designed to assess 
the Fe2+- and HIF-1-dependent cytoprotective activities of CDSO3 against various 
emphysematous insults via inflammation (CSE), oxidation (CSE and H2O2), elastolysis 
(HSE), and apoptosis (TSA and SU5416).  In addition, the cytoprotective activities of 
two known iron chelators, DFO and EDTA, will also be assessed to clarify whether Fe2+ 
chelating activity was sufficient to exhibit cytoprotective activity. 
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4.2 MATERIALS AND METHODS 
 
 4.2.1 Materials 
 
 CDSO3 and CD were prepared as sulfated and sulfated CA dehydropolymers, 
respectively, in the Desai laboratory, as described in Chapter 1.  They were supplied as 
either a solution (CDSO3BH) or lyophilized powder (CDSO3MT) and stored at -20 oC prior 
to use.  The monomer CA was purchased from Sigma-Aldrich (St. Louis, MO).  
Research-grade cigarettes, 3R4F, were obtained from the Kentucky Tobacco Research 
and Development Center (University of Kentucky, Lexington, KY).  Prior to each 
experiment, cigarette smoke extract (CSE) was freshly prepared by bubbling one 
research cigarette into 3 ml of the incubation media under ice using a smoking 
apparatus provided from Dr. Chu of the Hunger Holmes McGuire Richmond, VA 
Medical Center (Figure 4.1); this was considered to be 100 % CSE.  Hydrogen peroxide 
(H2O2, ACS reagent, 30% (w/v)) solution was purchased from ACROS Organics (New 
Jersey, NJ).  Its stock solution was prepared at 8.82 M (300mg/ml) in phosphate 
buffered saline (PBS; pH 7.4, Quality Biological) and stored at 4 oC prior to use.  Human 
sputum elastase (HSE) certified as 875 U/mg protein (100 % protein and >95.0 % 
purity) was purchased from Elastin Products Company, Inc. (Owensville, MO) as a 
lyophilized powder.  Its stock solution was prepared at 8,750 U/ml (10 mg/ml) in 50 % 
glycerol (Fisher Scientific) and 50 % 0.02 M sodium acetate (NaOAc; pH 5; Sigma 
Aldrich), stored in 50 µl aliquots at -20 oC, as recommended by the manufacturer for 
maximal stability.  Trichostatin A (TSA; >98.0% purity) was purchased from Sigma-
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Aldrich (St. Louis, MO) as a powder, and its stock solution was prepared at 6.61 mM (2 
mg/ml) in ethanol (Fisher Scientific) and stored in 20 µl aliquots at -20 oC.  SU5416 was 
a gift from Dr. Voelkel (VCU Pulmonary Medicine) and stored at -20oC prior to use.  The 
stock solution was prepared at 126 mM (30mg/ml) by dissolving SU5416 in 
dimethylformamide (DMF; Acros Organics) purged with nitrogen bubbled over 1 minute.  
Ferrous (Fe2+) sulfate heptahydrate (FeSO4•7H2O) and ferrous (Fe2+) chloride (FeCl2; 
>98.0 % purity) were purchased from Sigma-Aldrich and respectively stored at 4 and -
20 oC, prior to use.  Ferric (Fe3+) chloride (FeCl3; >98.0 % purity) was purchased from 
Spectrum Chemical Mfg. Corp (Gardena, CA) as an anhydrous sublimed powder and 
stored in a desiccator at room temperature prior to use.  Ethylenediaminetetraacetic 
acid (EDTA; 99.0 % purity) was purchased from Sigma-Aldrich as a disodium salt, and 
stored at room temperature.  Deferoxamine (DFO; ≥92.5 %purity) was a mesylate salt 
also obtained from Sigma-Aldrich and stored at -20 oC until use.  Echinomycin (Ech) 
and CAY10585 (CAY) were purchased from Cayman Chemical (Ann Arbor, MI) as 
crystalline solids; and their stock solutions were respectively prepared at 23 mM (10 
mg/ml) and 1.8 mM (2 mg/ml) in dimethyl sulfoxide (DMSO; Fisher Scientific) purged 
with nitrogen; they were stored in 50 µl aliquots at -20oC.   
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 4.2.2 Cell culture 
 
 Rat alveolar macrophage NR8383 cells and human adenocarcinomic alveolar 
epithelial A549 cells were obtained from the American Type Culture Collection (ATCC; 
Manassas, VA) and maintained as frozen cell banks at the Sakagami laboratory.  
NR8383 cells were seeded at concentrations of 0.1-0.4 x 106 cells/mL and A549 cells 
were seeded at concentrations of 0.002-0.01 x 106 cells/cm2, and propagated through 
culture in 10 or 15 ml of the culture media in 25 or 75 cm2 culture flasks (Corning 
Costar; Cambridge, MA), according to the protocol published by ATCC [Product 
Information Sheet: NR8383 (CRL-2192), ATCC; Product Information Sheet: A549 (CCL-
185), ATCC].  The media were the F-12K Medium (Kaighn’s Modification of Ham’s F-12 
Medium; ATCC) supplemented with 15% or 10% (v/v) fetal bovine serum (Invitrogen, 
Carlsbad, CA), respectively, and 1% (v/v) penicillin-streptomycin (Sigma-Aldrich).  The 
passages 8-30 were used in experiments.  In contrast, human lung microvascular 
endothelial (HMVEC-L) cells were purchased at passage 5 from Lonza (Walkersville, 
MD) and propagated in culture flasks according to the protocols published by Lonza 
[Product Information Sheet: Clonetics Endothelial Cell System, Lonza].  The cells were 
seeded at a density of 5,000 cells/cm2 and cultured in 10 or 15 ml of the Endothelial 
Growth Medium (EGM-2MV; Lonza).  The passages 5-10 were used in experiments.  
The NR8383, A549, and HMVEC-L cells were all maintained under the humidified 95% 
(v/v) air and 5% (v/v) CO2 at 37 oC in the incubator (Model 5410, NAPCO, Milliville, NJ) 
connected to a CO2 cylinder (National Welders, Richmond, VA).  The culture media 
were changed two to three times weekly, during which cell growth was monitored under 
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the Nikon-TMS phase contrast microscope (Image Systems, Columbia, MD).  Typically, 
the NR8383 and A549 cells reached confluence by 5-7 days and the HMVEC-L cells 
reached confluence by 5-9 days.  Upon confluence, the cells were passaged into well 
plates for experiments and/or new flasks for further propagation; otherwise they were 
frozen for cell bank storage following scraping (NR8383) or trypsin-EDTA treatment 
(A549 and HMVEC-L) with 95 % complete growth medium and 5 % DMSO (NR8383 
and A549) or 80 % EGM, 10 % DMSO, and 10 % FBS (HMVEC-L) in liquid nitrogen.       
 
 4.2.3 In vitro pro-inflammatory TNF- release  
 
 The NR8383 cells were plated at 0.05 x 106 cells/well in 0.2 ml F-12K media 
supplemented with 1% FBS in 48-well plates.  The cells were incubated with 0-25 µM 
CDSO3 in the absence or presence of 1 % CSE.  After 18 h incubation, the 
supernatants were obtained via centrifugation at 11,752 x g (12,000 rpm; Eppendorf 
5415 C; Westbury, NY) for 2 min.  The supernatants were then analyzed to determine 
TNF- released from the cells using the enzyme-linked immunosorbent assay (ELISA) 
kit (eBioscience), according to the manufacturer’s protocol [Product Information Sheet: 
Mouse TNF alpha ELISA Ready-SET-Go!; eBioscience].  
 
 4.2.4 In vitro trypan blue exclusion assay 
 
 In vitro protective activities were determined using the trypan blue exclusion 
(TBE) and lactate dehydrogenase (LDH) assays upon incubation with or without test 
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molecules (i.e. CDSO3, CD, CA, DFO, and EDTA) and/or CAY, Ech, Fe2+ (FeSO4 and 
FeCl2) and Fe3+ (FeCl3).  On day 1, the cells were seeded in a 200-µl system at a 
density of 0.05-0.15 x 106 cells/well of 48-well plates in FBS-depleted culture media (1% 
FBS).  Cell death was induced with 3-50 % CSE, 0.1 mM H2O2, 1 U/ml HSE, 1-2 µM 
TSA, or 1-50 µM SU5416.  CDSO3, CD, CA, DFO, and EDTA were tested at 0-25 µM.  
In some experiments, addition of HIF-1 inhibitors (Ech, 10 µM; or CAY,10 µM) or 
excess Fe2+  or Fe3+ at 50 µM were further added to explore and clarify CDSO3’s Fe2+- 
and HIF-1-dependent mechanism for cytoprotective (i.e. anti-cell death) activities.  
Following 18-24 h incubation at 37 oC, cell death was assessed using the TBE and LDH 
assays, as described in Appendix 1.  Briefly, while the incubation media were taken for 
the LDH release assay, the cells were harvested using trypsin-EDTA (A549 and 
HMVEC-L) or scraping (NR8383) for the TBE assay.  The cells were centrifuged at 
11,752 x g (12,000 rpm; Eppendorf 5415 C; Westbury, NY) for 3-4 minutes, and the cell 
pellets were re-suspended with 100 µl fresh incubation media.  Trypan blue solution, 4% 
(Amresco; Solon, OH) was added to the re-suspended cells and left at room 
temperature for 4-5 minutes.  The cell suspension was centrifuged again at 11,752 x g 
(12,000 rpm) for 3-4 min, and the cell pellets were re-suspended with 200 µl of fresh 
media and plated into new 48-well plates, and allowed to settle at room temperature for 
at least 2 h.  Using a microscope (Omax, Kent, WA) connected to ToupViewX (Omax, 
Kent, WA), at least 8-10 pictures were randomly captured to assure ≥300 cells to be 
counted.  For some preliminary experiments, only 100-200 cells were counted.  Figure 
4.2 shows a representative microscopic field image of the A549 cells following trypan 




Figure 4.2:  Representative microscopic field image of the A549 cells stained with 
trypan blue.  Dead cells are stained blue, while live cells remain clear. 
 
Following identification of over 300 cells, % dead cells was calculated from the following 
equation: 
 
% 𝑑𝑒𝑎𝑑 𝑐𝑒𝑙𝑙𝑠 = (
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑙𝑢𝑒 𝑐𝑒𝑙𝑙𝑠 
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 
)  ×  100 
 
 
 4.2.5 In vitro LDH release assay 
 
 The cells were seeded and treated, as discussed in 4.2.4.  After 18-24 h 
incubation, the cell supernatants and cell lysates were taken for the LDH assay and 
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centrifuged at 11,752 x g (12,000 rpm; Eppendorf 5415 C; Westbury, NY) for 3-4 
minutes.   The supernatants and cell lysates were analyzed by the LDH release assay 
according to the manufacturer’s protocol [Product Information Sheet TOX7: In vitro 
Toxicology Assay Kit, Lactic Dehydrogenase based Sigma-Aldrich].  The metabolic and 
chemical basis of the LDH assay is illustrated in Figure 4.3.  In principle, damaged cells 
release LDH, an enzyme that reduces nicotinamide adenine dinucleotide (NAD) to NAD 
+ hydrogen (NADH).  The resulting NADH is utilized in the stoichiometric conversion of 
a tetrazolium dye, which can be measured spectrophotometrically at 490 nm using a 
multi-mode microplate reader (Synergy2, Biotek).  The % LDH mass released is 
calculated as: 
 
% 𝐿𝐷𝐻 𝑚𝑎𝑠𝑠 = (
𝐿𝐷𝐻 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑓𝑟𝑜𝑚 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 𝑚𝑒𝑑𝑖𝑎
𝐿𝐷𝐻 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑓𝑟𝑜𝑚 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 𝑚𝑒𝑑𝑖𝑎 + 𝐿𝐷𝐻 𝑓𝑟𝑜𝑚 𝑐𝑒𝑙𝑙 𝑙𝑦𝑠𝑎𝑡𝑒











 4.2.6 Data Analysis 
 
 
 The data for each treatment groups were expressed as mean ± SD from more 
than triplicate experiments (n≥3).  Analysis of variance (ANOVA) was used to test 
statistical differences for group values.  In the event of significant difference in the 
ANOVA, the Tukey-Kramer multiple comparison test was carried out to identify group-
by-group statistical differences or the Dunnett’s test was carried out to identify statistical 
differences, compared to the negative control.  In ANOVA, Tukey-Kramer multiple 
comparison test, and Dunnett’s test, p<0.05 was considered to be statistically 
significant.  JMP Pro 12 Software (SAS, Cary, NC) was used for these statistical 






 4.3.1  In vitro protective effects of CDSO3 against CSE-induced pro-
 inflammatory TNF- release 
 
 Cigarette smoke contains thousands of chemical components, including ~ 1015 
reactive species in the gas phase alone, particularly high levels of nitric oxide, while the 
tar phase has an equally abundant number of reactive oxygen and nitrogen species 
(ROS, RNS), including phenols and quinone [Yoshida et al., 2007].  Failure of survival 
to cigarette smoke insults for alveolar macrophage is one of the early events in the 
pathobiologic cascade toward development of emphysema [Roth, 2008; Demedts et al., 
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2006].  It is believed that exposure to irritants such as cigarette smoke first activates 
alveolar macrophages to recruit neutrophils into the airways and cause epithelial 
inflammation via release of chemotactic factors like interleukins and chemokines 
[Barnes, 2004].  Indeed, it was recently reported that the pro-inflammatory mediator, 
TNF-, was primarily released from alveolar macrophages, and this is integral to cause 
inflammatory cell infiltration in cigarette smoke-induced emphysema [Churg et al., 
2004].  In this context, CDSO3 was tested for its protective activity against CSE-induced 
pro-inflammatory tumor necrosis factor  (TNF-) release in rat alveolar NR8383 
macrophages.  Figure 4.4 shows the TNF- release into the incubation media 
supernatants of the NR8383 macrophages after exposure to 1 % CSE in the absence or 
presence of CDSO3 at 1-25 µM.  CSE caused a significant 19.8-fold increase in TNF- 
release, compared to the vehicle control (40.3  797.3 pg/ml; p<0.05).  CDSO3 was 
shown to inhibit this CSE-induced TNF- release in a concentration-dependent manner 
at 1-25 µM, reaching significance at 5 µM.  CDSO3 at 5, 10, and 25 µM caused 
significant 49.3, 79.4, and 94.3 % inhibition, respectively (p<0.05).  Based on these 
results, it appears that CDSO3 is protective against CSE-induced pro-inflammatory 












Figure 4.4: TNF- release recovered from the incubation media supernatants of the rat 
alveolar NR8383 macrophages after exposure to vehicle (Vhcl) or 1 % CSE in the 
absence or presence of 1-25 µM CDSO3.  Data represents mean±SD from n=4; 
*p<0.05, compared to the vehicle (negative) control; **p<0.05, compared to the CSE-




















Vhcl 5 10 25















 4.3.2  In vitro protective activities of CDSO3 against cell death induced with 
 cigarette smoke extract (CSE) in the alveolar macrophage NR8383 cells  
 
 Once the alveolar macrophages are activated upon exposure to cigarette smoke, 
they recruit neutrophils into the airways and cause oxidative stress and inflammation.  
This induced oxidative stress and excessive production of elastolytic enzymes then 
progressively cause the alveolar wall destruction and airspace enlargement in 
emphysema [Barnes, 2004].  Thus, studies for CDSO3’s cytoprotective activities were 
also conducted in rat alveolar macrophage NR8383 cells upon cell death induced with 
CSE.  Figure 4.5 shows the effects of CSE concentration on NR8383 cell death, as 
determined by the (a) TBE and (b) LDH assays.  When the TBE assay was used, CSE 
at 3-50 % was shown to significantly cause cell death in a concentration-dependent 
manner, resulting in 4.3- and 8.7- fold greater % dead cells at 10 and 50 %, 
respectively, compared to the vehicle control (p<0.05; Figure 4.5.a).  Since the TBE 
assay could not avoid subjectivity in measurements, these TBE assay-based results 
were compared with those determined by a more objective, colorimetric method of LDH 
release assay, as shown in Figure 4.5.b.  Measured with increased absorbance at 490 
nm, CSE caused NR8383 cell death, again in a concentration-dependent manner, and 
became significant upon 10 and 50 % CSE exposure (p<0.05), but not at 1 %.  Based 
on these results, 10 % CSE was chosen to assess CDSO3’s cytoprotective activities in 
subsequent studies. 
 Figure 4.6 shows the cytoprotective activities of CDSO3 at 1-25 µM against 10 % 
CSE-induced NR8383 cell death, alongside those of the unsulfated oligomer CD and 
 56 
the monomer CA at 10 or 25 µM, as determined by the (a) TBE and (b) LDH release 
assays.  Using the TBE assay in Figure 4.6.a, CDSO3 at 1-25 µM was shown to 
significantly inhibit CSE-induced NR8383 cell death in a concentration-related fashion.  
In fact, 12.7 and 13.5 % dead cells seen for CDSO3 at 10 and 25 µM, respectively, 
were almost comparable with 8.3 % dead cells in the vehicle control, implying that 
CDSO3’s protective activities against this CSE-induced cell death were almost complete 
at these concentrations.  In contrast, CD (the unsulfated oligomer) produced only 46.5 
% protection at 25 µM, which was less potent than CDSO3 (83.9 % protection at 25 
µM); this % protection for CD was comparable to that for CDSO3 at 5 µM (Figure 4.6.a).  
In Figure 4.6.b, the cytoprotective activities measured by the LDH release assay are 
shown for CDSO3 (1-25 µM), CD (10 µM) and the monomer CA (10 µM).  Although 
statistical significance could not be established due to high variability values, a similar 
trend was seen that CDSO3 inhibited CSE-induced LDH release, i.e., cell death, in a 
concentration-related fashion.  Moreover, neither CD nor CA was cytoprotective at 10 
µM.  It appeared, based on these results, that CDSO3 was potently protective against 
CSE-induced cell death and that the TBE assay enabled more sensitive and 
reproductive assessments of cell death and cytoprotective activities, compared to the 
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Figure 4.5: Concentration-dependent CSE-induced cell death in NR8383 cells, as 
determined by the (a) TBE and (b) LDH assay.  Data represent mean±SD from n≥3; 
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Figure 4.6: In vitro cytoprotective effects of CDSO3, CD, and CA in CSE-induced cell 
death in NR8383 cells, as determined by the (a) TBE and (b) LDH assays.  Data 
represent mean±SD from n≥3; *p<0.05, compared to vehicle control; #p<0.05, 
compared to the CSE-induced control; $p<0.05, compared to the CSE-induced and 25 
















































 4.3.3 In vitro protective activities of CDSO3 against CSE-induced cell death in 
 the alveolar epithelial A549 cells and pulmonary vascular endothelial HMVEC-L 
 cells 
 
 Numerous studies have identified increased endothelial cell apoptosis in human 
COPD/emphysema [Fallica et al., 2014], and targeted induction of endothelial cell death 
has been shown to promote apoptosis of both endothelial cells and type II alveolar 
epithelial cells within the alveolar-capillary unit, resulting in emphysematous tissue 
remodeling [Giordano et al., 2008].   Therefore, the protective activities of CDSO3 
against 10 % CSE-induced cell death were further assessed in the (a) human alveolar 
epithelial A549 and (b) human pulmonary vascular endothelial HMVEC-L cells, 
determined by the TBE assay, as shown in Figure 4.7.  In both cell types, CDSO3 at 10 
µM alone did not cause cell death, while 10 % CSE increased % dead cells by 3.3- and 
1.5-fold, respectively.  However, CDSO3 at 10 µM caused significant 99.4 and 153.6 % 
protection against this induced cell death (p<0.05), respectively.  These results 
demonstrate that CDSO3 is also potently protective against lung epithelial and 
endothelial cell death induced with CSE. 
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Figure 4.7: In vitro cytoprotective effects of CDSO3 against CSE-induced cell death 
in (a) A549 and (b) HMVEC-L cells, as determined by the TBE assay.  + = present; - 
= absent.  Data represent mean±SD from n≥3; *p<0.05, compared to the vehicle 
control; #p<0.05, compared to the CSE-induced control, by ANOVA and Tukey’s 
multiple comparison test 
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 4.3.4  In vitro protective activities of CDSO3 against oxidative and elastolytic cell 
 death in the alveolar epithelial A549 cells 
 
 Because the alveolar wall septal destruction and loss in emphysema have been 
long known to be associated with induced oxidative stress and elastolytic activities in 
lungs, in addition to direct cigarette smoke insults [Yoshida, 2007], the cytoprotective 
activities of CDSO3 were then assessed in the A549 cells against (a) H2O2 and (b) 
HSE-induced cell death, respectively, determined by the TBE assay, as shown in Figure 
4.8.  H2O2 at 0.1 mM and HSE at 1 U/ml were found to induce A549 cell death 
significantly (p<0.05) by ~3.5 and ~4.5-fold, respectively.  However, CDSO3 at 1 and 10 
µM inhibited these induced cell death in a concentrated-related fashion.  The results at 
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Figure 4.8: In vitro cytoprotective effects of CDSO3 at 1 or 10 µM against (a) 0.1 mM 
H2O2-induced and (b) 1 U/ml HSE-induced A549 cell death, as determined by the TBE 
assay.  + = present; - = absent.  Data represent mean±SD from n≥3; *p<0.05, compared 
to the vehicle control; #p<0.05, compared to the induced control, by ANOVA and 
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 4.3.5  In vitro protective activities of CDSO3 against apoptotic lung cell death 
 
 In addition to oxidative stress and elastolysis, epigenetic modifications have been 
recently investigated in emphysematous lungs, thereby identifying reduced HDAC2 
activity, and induced alveolar epithelial and endothelial cell death via necrosis, 
apoptosis, and autophagy, alongside cellular matrix instability and breakdown [Mizuno 
et al., 2011].  Therefore, the in vitro protective effects of CDSO3 against cell death 
induced with an HDAC inhibitor, TSA, in the (a) A549 and (b) HMVEC-L cells, were also 
tested, as determined by the TBE assay (Figure 4.9).  TSA at 2 µM significantly 
increased % dead cells in the A549 and HMVEC-L cells by about 3.5- and 4.6- fold, 
respectively.  However, CDSO3 at 10 µM again significantly inhibited such TSA-induced 
cell death by 68.6 and 63.6 % (p<0.05), respectively, suggesting that CDSO3 was also 
capable of potent cytoprotection against apoptotic cell death induced with the epigenetic 

























Figure 4.9: In vitro cytoprotective effects of CDSO3 at 1 or 10 µM against 2 µM TSA-
induced cell death in (a) A549 and (b) HMVEC-L cells, as determined by the TBE 
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to the vehicle control; #p<0.05, compared to the TSA-induced control, by ANOVA and 
Tukey’s multiple comparison test 
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 Epigenetic modifications of HDAC inhibition are suggested to lead to apoptotic 
cell death in emphysematous lungs, at least in part, via impaired VEGF and its receptor 
signaling [Mizuno et al., 2011; Kasahara et al., 2000].  In fact, as shown in Figure 4.10, 
a VEGF receptor antagonist, SU5416, caused A549 cell death in a concentration-
dependent manner, reaching significance in its cell death induction at ≥ 10 µM (p<0.05).  
Hence, the in vitro protective activities of CDSO3 at 10 µM were examined in the 
HMVEC-L cells against cell death induced with SU5146 at 10 or 25 µM, determined by 
the TBE assay, as shown in Figure 4.11.  SU5416 increased % dead cells by ~3.5 and 
~5.0-fold at 10 and 25 µM, respectively.  Against these induced cell death, CDSO3 at 
10 µM was able to produce significant inhibition by 86.1 and 50.7 %, respectively 
(p<0.05).  It became clear therefore that CDSO3 potently inhibited lung cell death 




























Figure 4.10: Effects of SU5416 concentration on A5419 cell death induction, as 
determined by the TBE assay.  Data represent mean±SD from n≥3; *p<0.05, compared 





















Figure 4.11: In vitro protective activities of 10 µM CDSO3 against 10 or 25 µM SU5416-
induced HMVEC-L cell death, as determined by the TBE assay.  + = present; - = 
absent.  Data represent mean±SD from n≥3; *p<0.05, compared to the vehicle control; 
#p<0.05, compared to the SU5416 (10 µM)-induced control; $p<0.05, compared to the 
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 4.3.6  Fe2+- and  HIF-1-dependent mechanisms for CDSO3’s anti-cell death 
 activities 
 
 While CDSO3 at 10 µM consistently exhibited potent protective activities against 
lung epithelial and endothelial cell death induced with different emphysematous insults, 
its mechanism was still unknown.  Based on a hypothesis that CDSO3’s Fe2+ chelating 
activity inhibits Fe2+-dependent HIF-degrading enzymes, HIF-PHDs, thereby stabilizing 
HIF-and elevating HIF-regulating VEGF, for these anti-cell death activities, effects of 
HIF-1 inhibitors (Echinomycin and CAY) and excess Fe2+ or Fe3+ on CDSO3’s 
protective activities were studied in the A549 and HMVEC-L cells upon cell death 
induced with CSE, TSA, or SU5416, as shown in Figures 4.12-4.16.  In the A549 cells, 
as shown in Figures 4.12 and 4.13, 99.4 and 68.6 % protective activities for CDSO3 at 
10 µM against the CSE- and TSA-induced cell death, respectively, were near 
completely opposed by addition of HIF-1 inhibitors, 10 µM Ech and CAY, as well as 
excess Fe2+ (50 µM FeSO4).  In the HMVEC-L cells, as shown in Figures 4.14-4.16, 
50.7-86.1 % protective activities for 10 µM CDSO3 against the TSA- and SU5416-
induced cell death were again near completely negated by addition of Ech, CAY, and 
excess Fe2+ (50 µM FeSO4 or FeCl2).  However, as shown in Figure 4.16, addition of 
excess Fe3+ (50 µM FeCl3) failed to oppose CDSO3’s anti-cell death activities.  
Collectively, these results were consistent with CDSO3’s Fe2+- and HIF-1-dependent 







Figure 4.12: Effects of 10 µM echinomycin (Ech; a HIF-1 inhibitor) and 50 µM FeSO4 
(i.e., excess Fe2+) on CDSO3’s protective activities at 10 µM against 10 % CSE-induced 
cell death in A549 cells, as determined by the TBE assay.  + = present; - = absent.  
Data represent mean±SD from n≥3; *p<0.05, compared to the vehicle control; #p<0.05, 
compared to the CSE-induced control; $p<0.05, compared to the TSA-induced and 
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Figure 4.13: Effects of 10 µM CAY10585 (CAY; a HIF-1 inhibitor), 10 µM echinomycin 
(Ech; a HIF-1 inhibitor) and 50 µM FeSO4 (i.e., excess Fe2+) on CDSO3’s protective 
activities at 10 µM against 2 µM TSA-induced cell death in A549 cells, as determined by 
the TBE assay.  + = present; - = absent.  Data represent mean±SD from n≥3; *p<0.05, 
compared to the vehicle control; #p<0.05, compared to the TSA-induced control; 
$p<0.05, compared to the TSA-induced and CDSO3-treated group, by ANOVA and 
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Figure 4.14: Effects of 10 µM echinomycin (Ech; a HIF-1 inhibitor) and 50 µM FeSO4 
(i.e., excess Fe2+) on CDSO3’s protective activities at 10 µM against 2 µM TSA-induced 
cell death in HMVEC-L cells, as determined by the (a) TBE and (b) LDH release assay.  
+ = present; - = absent.  Data represent mean±SD from n≥3; *p<0.05, compared to 
vehicle control; #p<0.05, compared to the TSA-induced control; $p<0.05, compared to 
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Figure 4.15: Effects of 10 µM CAY10585 (CAY; a HIF-1 inhibitor) and 50 µM FeCl2 
(i.e., excess Fe2+) on CDSO3’s protective activities at 10 µM against 25 µM SU5416-
induced HMVEC-L cell death, as determined by the TBE assay.  + = present; - = 
absent.  Data represent mean±SD from n≥3; *p<0.05, compared to the vehicle control; 
#p<0.05, compared to the SU5416-induced control; $p<0.05, compared to the SU5416-
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Figure 4.16: Effects of 10 µM CAY10585 (CAY; a HIF-1inhibitor) and 50 µM FeCl2 
and FeCl3 (i.e., excess Fe2+) on CDSO3’s protective activities at 10 µM against 10 µM 
SU5416-induced HMVEC-L cell death, as determined by the TBE assay.  + = present; - 
= absent.  Data represent mean±SD from n≥3; *p<0.05, compared to the vehicle 
control; #p<0.05, compared to the SU5416-induced control; $p<0.05, compared to the 
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 4.3.7  In vitro protective activities of other Fe2+ chelator molecules against 
 SU5416-induced A549 cell death 
 
 To examine whether Fe2+ chelating activities alone universally produce protective 
activities against emphysematous cell death, two other known Fe2+ chelators molecules, 
DFO and EDTA, were tested for their cytoprotective activities against SU5416-induced 
A549 cell death determined by the TBE assay.  As shown in Figure 4.17, unlike CDSO3 
exerting 72.6 % cytoprotection, 4.0-fold increase of % dead cells induced with 10 µM 
SU5416 were unable to be inhibited by either DFO or EDTA at 10 µM.  This in turn 
implied that CDSO3 is unique and different from DFO or EDTA as a Fe2+ chelator 
molecule capable of cytoprotection, presumably because CDSO3 is relatively lipophilic 
(log D ~ 1), while DFO and EDTA are hydrophilic and highly charged (log D ~ -2.2 and 
~-0.8, respectively). 



























Figure 4.17: In vitro protective activities of CDSO3, DFO, and EDTA at 10 µM against 
SU5416-induced cell death, as determined by the TB assay.  + = present; - = absent.  
Data represent mean±SD from n≥3; *p<0.05, compared to the vehicle control; #p<0.05, 
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 4.3.8  Comparisons of the in vitro protective activities of two different batches of 
 CDSO3 
 
 As discussed in Chapter 3, two different batches of CDSO3 were synthesized, 
i.e., CDSO3BH and CDSO3MT [Monien et al., 2006; Thompson et al., 2015], and 
provided for our experiments.  As shown in Table 3.1, their elemental compositions and 
distribution coefficients (log D), determined by Monien [2006] and Thompson [2015], 
were different.  The in vitro ferrous (Fe2+) chelating activities of both batches were then 
determined in Chapter 3, revealing comparable IC50 values of 23.3±2.1 and 17.0±1.4 
µM.  It was therefore of interest to compare the in vitro cytoprotective activities of these 
two batches.  Figure 4.18 shows the comparative in vitro cytoprotective effects of (a) 
CDSO3BH and (b) CDSO3MT at 10 µM against 10-µM SU5416-induced A549 cell death, 
as determined by the TBE assay.  CDSO3BH and CDSO3MT1 at 10 µM produced 
comparable 72.6±3.1 and 80.7±3.4 % protection against SU5416-induced A549 cell 
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Figure 4.18: Protective effects of CDSO3BH and CDSO3MT at 10 µM against 10 µM 
SU5416-induced A549 cell death, as determined by the TBE assay.  + = present; - = 
absent.  Data represent mean±SD from n≥3; *p<0.05, compared to the vehicle control; 
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4.4  DISCUSSION 
 
 
 In this chapter, the ELISA assay was used to assess CSE-induced pro-
inflammatory TNF- release in alveolar macrophages.  In contrast, the TBE and LDH 
assays were employed to assess the Fe2+ chelation-dependent HIF-1 up-regulatory in 
vitro cytoprotective activity of CDSO3 against inflammatory, oxidative, elastolytic, and 
apoptotic cell deaths, in alveolar macrophages, epithelial, and endothelial cells.  
Furthermore, its cytoprotective activity of two other well-known chelators, DFO and 
EDTA were also assessed.  CDSO3 was shown to protect against CSE-induced TNF- 
release, while also being the only chelator shown to exhibit potent protective activities 
against these various stimuli, suggesting its unique ability to enter these cells that have 
been suggested in the pathobiological mechanism of emphysema in order to exert its 
cytoprotection.  These findings of CDSO3’s protective activities are promising to further 
study its ability to reverse lung damages in established emphysema in vivo. 
 
 
 4.4.1 CDSO3 as a cytoprotective drug against inflammatory, oxidative, and 
 elastolytic cell death 
 
 The widely accepted cornerstones of emphysema pathogenesis are persistent 
inflammation, oxidative stress, and protease/anti-protease imbalance [Suki et al., 2003; 
Barnes et al., 2003].  First, the inhalation of noxious particles from cigarette smoke 
causes the massive influx of inflammatory cells, such as alveolar macrophages and 
neutrophils, into the luminal airways and lung tissues, which release pro-inflammatory 
mediators into the lung [Roth, 2008; de Boer WI et al., 2005].  The pro-inflammatory 
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factors released by activated immune cells stimulate the resident cells to produce and 
secrete additional pro-inflammatory factors, thereby attracting more immune cells, 
sustaining the cycle of this inflammatory process [Roth, 2008].  Secondly, the 
inflammatory cells (macrophages and neutrophils) release proteolytic enzymes, which 
causes an imbalance between proteases and anti-proteases in the lungs, resulting in an 
increased in proteolytic activity [Demedts et al., 2006; Roth, 2008].  And third, cigarette 
smoke or inflammatory leukocytes and epithelial cells also generate oxidants, resulting 
in oxidative stress.  This oxidative stress can further contribute to the protease/anti-
protease imbalance and the inflammatory reaction by activating the transcription of pro-
inflammatory genes via activation of the transcription factor NF-B [Demedts et al., 
2006].  Furthermore, oxidative stress can lead to cell death and can cause damage to 
the lung extracellular matrix [Demedts et al., 2006].   
 The unsulfated and sulfated dehdryopolymers (DHPs), CD and CDSO3, 
alongside the caffeic acid (CA) monomer, have recently been shown to exhibit triple 
inhibitory activity against elastase, oxidation and inflammation in vitro, with CDSO3 
being most potent, as summarized in Table 1.4 [Saluja et al, 2013].  CDSO3 was also 
shown to inhibit 1% CSE-induced TNF- release in a concentration-dependent manner 
from 1-25 µM, with 5, 10, and 25 µM causing significant 49.3, 79.4, and 94.3 % 
inhibition, respectively (p<0.05; Figure 4.4).  It was therefore hypothesize that CDSO3 
could also protect against emphysematous cell death induced by these three known 
mechanisms.  Thus, the cytoprotective activity of CDSO3, along with CD and CA, were 
tested against inflammatory (CSE)-, oxidative (CSE and H2O2)-, and elastolytic (HSE)-
induced alveolar macrophage, epithelial, and endothelial cell death using the TBE and 
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LDH assays.  It was found that CD at 25 µM could only produce 46.5 % protection, 
which was less potent than CDSO3 (83.9 % protection at µM), assessed by the TBE 
assay; however, neither CD nor CA was cytoprotective at 10 µM against 10 % CSE, 
when assessed by the LDH assay.  CDSO3 at 10 µM exhibited potent 84.0-153.9 % 
cytoprotection against 10% CSE-, 0.1 mM H2O2-, and 1 U/ml HSE-induced alveolar 
macrophage, epithelial, and endothelial cells (Table 4.1).  These data were encouraging 
to showing that CDSO3 produced triple protection against the multi-faceted 
mechanisms believed to be the cornerstones of the pathogenesis of emphysema.   
 
 4.4.2  CDSO3 as a cytoprotective drug against apoptotic cell death 
 
 It has been widely reported that increased apoptosis of alveolar septal cells is 
observed in the lungs of patients with COPD/emphysema [Demedts et al., 2006; Imai et 
al., 2005; Kasahara et al., 2000; Yokohori et al., 2004].  Furthermore, epigenetic 
modifications of HDAC inhibition are suggested to lead to apoptotic cell death in 
emphysematous lungs, at least in part, via impaired VEGF and its receptor signaling 
[Mizuno et al., 2011; Kasahara et al., 2000].  Therefore, the protective activity of CDSO3 
was assessed against alveolar epithelial and endothelial cell death induced with TSA 
(an HDAC inhibitor) and SU5416 (a VEGF receptor blockade) using the TBE.  CDSO3 
at 10 µM potently inhibited these induced cell deaths by 63.6-86.1 % in both alveolar 
epithelial and endothelial cells (Table 4.1), clearly suggesting that CDSO3 was 
protective against cell death induced with an epigenetic HDAC inhibitor as well as a 
VEGF receptor blocker.  
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Table 4.1: The % inhibition of CDSO3 at 10 µM against emphysematous cell death induced with different stimuli in 
alveolar macrophages (NR8383), epithelial (A549), and endothelial (HMVEC-L) cells, as determined by the trypan blue 
exclusion (TBE) assay. 













10 % CSE 4.3-fold 84.0±12.8 3.3-fold 99.4±12.5 1.7-fold 153.9±18.2 
0.1 mM H2O2 - - 3.9-fold 102.9±3.9 - - 
1 U/ml HSE - - 6.7-fold 91.7±24.1 - - 
2 µM TSA - - 3.5-fold 68.6±19.5 5.0-fold 63.6±13.0 
10 µM SU5416 - - 4.3-fold 72.6±5.3 3.5-fold 86.1±14.2 
1Increase in % dead cells, as compared to the vehicle (negative) control. 
2Values shown as mean±SD from n≥3 
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  4.4.3 CDSO3’s cytoprotection is Fe2+- and HIF-1-dependent 
 
 While CDSO3 at 10 µM consistently exhibited potent protective activities against 
lung epithelial and endothelial cell death induced with different emphysematous insults, 
its mechanism was still unproven.  Based on a hypothesis that CDSO3’s Fe2+ chelating 
activity inhibits Fe2+-dependent HIF-degrading enzymes, HIF-prolyl hydroxylases (PHD), 
thereby stabilizing HIF-a and elevating HIF-regulating VEGF, for these anti-cell death 
activities, effects of HIf-1 inhibitors (echinomycin and CAY10585) and excess Fe2+ or 
Fe3+ on CDSO3’s protective activities were studied in the A549 and HMVEC-L cells 
upon cell death induced with CSE, TSA, or SU5416.  The cytoprotective activities of 
CDSO3 at 10 µM were near completely opposed by addition of HIF-1 inhibitors, 10 µM 
echinomycin (Ech) and CAY10585 (CAY), as well as excess Fe2+ (50 µM FeSO4).  
However, addition of excess Fe3+ (50 µM FeCl3) failed to oppose CDSO3’s anti-cell 
death activities.  This can be explained by the lack of ferric (Fe3+) chelating activity with 
CDSO3 at 10 µM, as discussed in Chapter 3.  Collectively, these results were 
consistent with CDSO3’s Fe2+- and HIF-1-dependent mechanism.   
 
 4.4.4 DFO and EDTA are Fe2+ chelators but not cytoprotective 
 
 To examine whether Fe2+ chelating activities alone universally produce protective 
activities against emphysematous cell death, two other known Fe2+ chelators molecules, 
deferoxamine (DFO) and ethylenediaminetetraacetic acid (EDTA), were tested for their 
cytoprotective activities against SU5416-induced A549 cell death determined by the 
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TBE assay.  As shown in Figure 4.17, unlike CDSO3 exerting 72.6 % cytoprotection, the 
4-fold increased % dead cells induced with 10 µM SU5416 were unable to be inhibited 
by either DFO or EDTA at 10 µM.  This implied that CDSO3 is unique and different from 
DFO or EDTA as a Fe2+ chelator molecule capable of cytoprotection.  It was reported 
Thompson [2015] that the log D value of CDSO3 is ~1, making it 10 times more 
concentrated in the organic phase than the aqueous phase.  Although CDSO3 is a large 
molecule containing charges, its aromatic backbone imparts over hydrophobic 
character, allowing it to penetrate the membrane and enter the cell where it exerts its 
effects.  Conversely, DFO (log D = -2.2) and EDTA (log D = -0.8) are known to be highly 
hydrophilic molecules, therefore, although they both have Fe2+ chelation IC50 values of 
31.8±2.1 (95% CI: 27.1, 36.6) and 24.6±4.8 (95% CI: 13.6, 35.6) µM (Chapter 3), these 
molecules are not able to penetrate the membrane to exert their effects inside the cell.  
 
 
4.5  CONCLUSIONS 
 
  
 CDSO3 was clearly shown to exhibit potent cytoprotective activity against 
release of the pro-inflammatory cytokine, TNF-, in alveolar macrophages.   CDSO3 
was also protective against inflammatory (CSE), oxidative (CSE and H2O2), elastolytic 
(HSE), and apoptotic (TSA and SU5416) cell death, in alveolar macrophages, epithelial, 
and endothelial cells.  Furthermore, the molecular mechanism of this anti-cell death 
activity is suggested to involve Fe2+ chelation up-regulation HIF-1.  However, the Fe2+ 
chelators, DFO and EDTA, did not exhibit the same cytoprotection, implying that 
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REVERSAL OF EMPHYSEMA INDUCED BY VEGF RECEPTOR BLOCKADE IN 







 As a triple-action inhibitor of oxidative stress, inflammation, and neutrophil 
elastase, CDSO3 remarkably attenuates the development of emphysema, when dosed 
to the lung in a preventative and interventional manner [Saluja et al., 2013,2014].  
However, it is more important to reverse emphysema so as to develop a cure, such that 
epigenetic modifications in the emphysematous lung have received considerable 
attention to identify the responsible factor for progressive destruction and loss of the 
alveolar septa.  Hypothesizing that CDSO3 is a lipophilic Fe2+ chelator enabling 
protection against epigenetically-induced apoptotic lung cell death, CDSO3’s 
cytoprotective activities for repairing emphysematous lungs via recovery of “HIF-
1/VEGF deficiency” were assessed against various emphysematous cell death in 
Chapter 4.  In Chapter 4, CDSO3’s mechanism for cytoprotection was also clarified.  
However, it was still uncertain whether CDSO3 is also effective in vivo in the animal 
model of emphysema, in the especially epigenetically-relevant model.  Hence, this 
chapter was designed to test CDSO3’s Fe2+- and HIF-1-dependent reversal of lung 
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damages in an in vivo rat model of apoptotic emphysema induced by VEGF receptor 
blockade [Kasahara et al., 2000].  It was also aimed to clarify whether lung functional 
activity could be correlated with alveolar morphological airspace enlargement and 
destruction, to define established emphysema.  The in vivo functional activity was 
assessed by the treadmill exercise endurance (EE) test, whereas the in vivo 
morphological alveolar airspace enlargement and destruction were quantified by 
measuring the mean linear intercept (MLI) and destructive index (DI), respectively.  The 
lung tissue expressions of HDAC2, HIF-1a, VEGF, BAX, and cleaved caspase-3 were 
measured by Western blot in an attempt to clarify the mechanism of CDSO3’s reversal 
of established emphysema. 
 
5.2  MATERIALS AND METHODS 
 
 5.2.1 Materials 
 
 CDSO3 was prepared as described in previous chapters at the Desai laboratory, 
and stored at -20 oC prior to use.  Only one batch referred to as CDSO3BH in Chapter 3 
was used, supplied as 5 mM lyophilized powder.   SU5416 was a gift from Dr. Voelkel 
(VCU Pulmonary Medicine) and stored at -20 oC prior to use.  FeSO4•7H2O was 
purchased from Sigma-Aldrich and stored at 4 oC, prior to use.  Agarose solution at 0.5 
% was prepared by slowly adding agarose (Invitrogen, Carlsbad, CA) into 80 oC DDW to 
complete its dissolution in a beaker on a magnetic hotplate stirrer; temperature was 
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then maintained at 50 oC prior to use.  Isoflurane was purchased from Webster 
Veterinary Supply, Inc. (Sterling, MA) and stored at room temperature.    
 
 
 5.2.2 Animals 
 
 
 This research adhered to the NIH Principles of Laboratory Animal Care (NIH 
publication #85-23, revised in 1985) under the protocol approved by the Institutional 
Animal Care and Use Committee (IACUC) at Virginia Commonwealth University (VCU; 
Protocol AD20086).  Male Sprague-Dawley rats (specific-pathogen free, 8-9 weeks of 
age), weighing 250-275 g, were received from Hilltop Lab Animals, Inc. (Scottdale, PA) 
and acclimated for more than 3 days prior to use.  Temperature (20-23oC), relatively 
humidity (40-70%) and light-dark cycling (12-12 h; the light cycle was between 6 a.m. 
and 6 p.m.) were tightly controlled and maintained.   
 
 
 5.2.3 Study protocol 
 
 Figure 5.1 outlines the overall experimental protocol to 1) develop and establish 
emphysema in rats, induced with SU5416; 2) treat emphysematous animals with 
CDSO3 or saline; and 3) to assess functional treadmill exercise endurance, followed by 
animal sacrifice and lung harvest.  A total of 42 animals were used and divided into the 





 Induction Treatment N 
Group 1 Saline Saline 14 
Group 2 Saline CDSO3 2 
Group 3 SU5416 Saline 10 
Group 4 SU5416 CDSO3 12 
Group 5 SU5416 CDSO3 + FeSO4 4 
 
Following acclimatization, rats were trained for two weeks to run on the rodent treadmill 
(Accuscan Instruments, Inc.; Figure 5.2), according to our in-house training protocol 
described in Appendix 2.  On Day 1, rats were tested to ensure completion of their 
learning (pre-experimental EE), according to our testing protocol described in Appendix 
2. Groups 3, 4, and 5 of animals received a single subcutaneous (SC) injection of 
SU5416 at 20 mg/kg to induce non-inflammatory, apoptotic, experimental emphysema 
[Kasahara et al., 2000]. SU5416 was suspended in saline or 0.9 % NaCl containing 0.5 
% carboxymethylcellulose sodium, 0.9 benzylalcohol, and 0.4% Tween 80, and 
subcutaneously injected as 5 mg/ml suspension without a use of anesthesia; Groups 1 
and 2 of animals received saline. Rats were left untreated in the animal facility for 3 
weeks, while treadmill training continued to maintain their learning, as described in 
Appendix 2.  On Day 21, their pre-dose exercise endurance was determined to ensure 
the development of emphysema from reduced EE times. Groups 2 and 4 received an 
orotracheal (OT) instillations of CDSO3 at 60 µg/kg three times a week for 2 weeks; 
Group 5 received OT CDSO3 at 60 µg/kg premixed with 10 mM FeSO4; Groups 1 and 3 
received OT saline.  On Day 35, all animals were tested for their post-dose EE.  The 
animals were then anesthetized with an intraperitoneal injection of urethane at 1 g/kg.  
The trachea was exposed and cannulated through an incision made on the trachea.  
After the chest cavity was opened, the animals were sacrificed by exsanguination by 
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cutting the abdominal aorta.  The lung was carefully removed from the body, and the left 
lung was then inflated with ~ 8 ml of a 0.5 % agarose solution warmed at 45 oC through 
the tracheal cannula at a hydrostatic pressure of 20 cm; the bronchi to the right lung 
lobes were closed with a suture.  The fully-inflated left lungs were placed on ice for ≥5 
min to solidify the luminal agarose, followed by fixation in 10 % buffered formalin at 4oC 
over 24 h.  The fixed lung tissues were sent to the VCU Anatomical Pathology 
Laboratory to be embedded in paraffin blocks, followed by hematoxylin-eosin (HE) 
staining of their 4 µm-thick alveolar section slides.  The lung sections were used to 
quantify airspace enlargement (mean linear intercept, MLI) and alveolar destruction 










Figure 5.1:  Experimental protocol to assess the in vivo lung repairing effects of CDSO3 administered into the lung in the 
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 5.2.4 Orotracheal pulmonary instillation 
 
 CDSO3 or saline was administered to the lungs by orotracheal instillation under 
short anesthesia with isoflurane.  Each rat was anesthetized in a chamber box with 4 % 
(v/v) isoflurance vapors generated from a vaporizer (Ohmeda Tech 4 Surgivet, Smiths 
Medical North America, Waukesha, WN) in 95% oxygen and 5% air as a carrier gas 
(National Welders, Richmond, VA) at 3.5 l/min.  Sufficient anesthesia was typically 
attained in 5 min, ensured by the absence of corneal and pedal reflexes.  Subsequently, 
the animal was placed in a supine position on a surgical board inclined at 60o under a 
heat lamp.  The tracheal entry lumen was visually confirmed through the oral cavity 
using a small animal fiber-optic laryngoscope (Welch Allyn, Skaneateles Falls, NY).  
Then, 0.1 ml of CDSO3 at 60 µg/kg or saline was directly instilled into the lung using a 
PennCentury Microsprayer (Wyndmoor, PA); the tip of the Microsprayer was positioned 
just before the tracheal bifurcation.  The animals were held in an upright position for 1 
min to avoid cough reflexes before returning to the cages.  The entire instillation 
operation was typically completed within 6 min of the isoflurane anesthesia, after which 
the animals regained consciousness in 4 min.    
 
 
 5.2.5 Airspace enlargement 
 
 
 Alveolar airspace enlargement was quantified by measuring the MLI, as 
described by Thurlbeck [1967] and slightly modified in-house.  The H&E-stained lung 
sections were viewed under the microscope at 25X magnification, and 5 airspace 
 94 
images were randomly selected, photographed using the Axiovision software (Allied 
High Tech Products, Rancho Dominguez, CA) and printed out on 8x11-sized paper.  On 
each image, 5 equally spaced lines (space: 513 µm; line length: 3540) were drawn 
(Figure 5.3), and their intercepts with the alveolar walls in the line length were counted 
to determine the MLI values (3540 µm/the number of intercepts).  The MLI value for 
each animal was thus calculated as an average of the 25 MLI values (5 horizontal lines 




















Figure 5.3:  Representative histological hematoxylin-eosin (H&E)-stained micrograph of 
the left lung lobes taken on day 35 at 25x magnification used to determine the MLI.  
Five equally spaced lines (space: 513 µm; line length: 3540) are drawn over each image 
and their intercepts with the alveolar walls (stained purple) in the line length were 

















 5.2.6 Alveolar destruction 
 
 
 Alveolar destruction was quantified by measuring the destructive index (DI), as 
described by Eidelman [1991] and modified in-house.  The H&E-stained lung sections 
were viewed under the microscope at 100X magnification and 50-60 airspace images 
were randomly taken (Figure 5.4).  User Microsoft PowerPoint, each of the images was 
placed on a slide with a grid of 66 equally spaced dot points placed over each image.  
The alveolar spaces and duct spaces surrounding each point was carefully inspected 
and classified as either normal (N) or destroyed (D).  Only dot points falling on whole 
alveoli and/or alveolar duct spaces were counted.  Points falling on other structures, 
such as duct walls and alveolar walls, were not included.  Both alveolar spaces and 
alveolar duct spaces were considered normal if they were surrounded by intact walls 
disrupted in only one place.  A structure was considered to be destroyed if a) the wall of 
an avelolus was disrupted in two or more places, b) there were more than two 
disruptions of adjacent aloveli that opened into a single duct space, 3) when a duct 
space contained two or more islands of lung parenchyma within its lumen, or 4) when a 
structure was lined with cuboidal epithelium but was clearly not an airway, with or 
without breaks in the walls.   Over 2,000 dot points were assessed, from which the % DI 










Figure 5.4:  Representative histological hematoxylin-eosin (H&E)-stained micrograph 
(100x magnification) of the left lung lobe taken at day 35 used to determine the DI.  The 
red arrows are pointed towards destruction in the alveolar walls, so that the   


















 5.2.7 Western blot 
 
 
 Lung tissue (300 mg) was minced and lysed in 1 ml of a lysis buffer containing 
150 mM NaCl (Fisher Scientific), 50 mM Tris (pH 8.0, Bio-Rad Laboratories), 1% NP-40 
(Fisher Scientific), and protease inhibitor (1 tablet in 10 ml of lysis buffer, Roche 
Diagnostics) using a homogenizer (Pro 200; Pro Scientific, Inc.) for 2 minutes.  The 
tissue was allowed to rest for 15 minutes on ice, vortexed, and centrifuged (Aventi JE 
Centrifuge; Beckman Coulter) at 16,000 g at 4oC.  The supernatant was stored at -70oC 
prior to use.  The protein concentration was quantified by bicinchoninic acid assay 
(Pierce).  The lung tissue samples were then prepared at a concentration of 2.5 µg/µl.   
In total, 40-70 µg of protein from the whole-lung lysates were loaded onto 10% Mini-
Protean Precast Gels (Bio-Rad Laboratories) and subjected to Tris/Glycine/sodium 
dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (Bio-Rad Laboratories) at 100 
V for about 90 minutes.  The protein was transferred from the gel to a 0.2 µm 
nitrocellulose membrane (Bio-Rad Laboratories) for ~90 minutes at 100 V.  The 
membranes were washed in PBS containing 0.1% Tween-20 (pH 7.5) for 5 minutes, 
then blocked in 5% (w/v) non-fat dried milk (Kroger) in TBS or PBS for 60 minutes on a 
slow rocker at room temperature.  The membrane was then incubated with primary 
antibodies against HDAC2 (rabbit monoclonal, Santa Cruz, sc-7899), HIF-1 (rabbit 
polyclonal, Santa Cruz, sc-10790), cleaved caspase-3 (rabbit monoclonal, Cell 
Signaling, 9664-s), VEGF (mouse monoclonal, Santa Cruz, sc-7269 ), or BAX (rabbit 
monoclonal, Cell Signaling, 2772s) for 60 minutes at room temperature on a slow 
rocker.  The membranes continued to be incubated in the primary antibody at 4 oC on a 
slow rocker overnight.  Subsequently, the membranes were then washed for 10 minutes 
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three times in PBS or TBS.  The membrane was then allowed to incubate in anti-mouse 
or anti-rabbit secondary antibodies raised in goat conjugated with HRP (Bio-Rad 
Laboratories) on the slow rocker at room temperature for 80 minutes, then washed for 
15 minutes three times in PBS or TBS.  The membranes were allowed to incubate in 
SuperSignal West Pico Chemiluminescent Substrate (1:1 stable peroxide solution and 
liminal enhancer solution) for 1 minute, then developed onto BioExcell Autoradiographic 
Films. 
 
 5.2.8 Data analysis 
 
 
 The data for each treatment groups were expressed as mean ± SD.  Analysis of 
variance (ANOVA) was used to test statistical differences for individual values.  In the 
event of significant difference in the ANOVA, the Tukey-Kramer multiple comparison 
test was carried out to identify group-to-group statistical differences.  In both ANOVA 
and Tukey-Kramer multiple comparison test, p<0.05 was considered to be statistically 





 All animals tolerated SU5416 or saline SC injection and/or saline, CDSO3 and/or 
FeSO4 spray-instillations to the lung over the two week period, based on monitoring of 
appearance, posture, mobility, appetite, and body weight gain, with the exception of 
three animals (TR209, 210, and 211) that showed reduced body weight gain during the 
CDSO3 dosing period. Note however that these rats still exhibited improved exercise 
endurance, as shown in Figures 5.5 and 5.6. 
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 5.3.1 Treadmill exercise endurance impairment and its improvement by CDSO3 
 
 Figures 5.5 show the treadmill EE time and its change in each animal receiving 
different treatment groups.  Healthy, untreated control animals ran 43.3±6.8 min on the 
treadmill until exhaustion, and two-week lung administration of CDSO3 at 60 µg/kg 
alone did not alter the running times, i.e., 41.6±0.9 min.  This demonstrated that CDSO3 
by itself does not cause functional EE impairment.  In contrast, SC injection of SU5416 
at 20 mg/kg significantly (p<0.05) reduced the EE times by 80.8 % (8.3±2.8 min), shown 
as post-induction, pre-treatment EE values in Figure 5.5, which confirmed the 
development of emphysema.  When these emphysematous rats were treated with 
saline for two weeks, the post-treatment EE values remained unimproved at 8.5±3.6 
min, or impaired by average 80.4 %.  However, when CDSO3 was administered to the 
lungs at 60 µg/kg for 2 weeks, the EE values were significantly (p<0.05) improved in all 
the rats by average 66.5 % to 31.9±7.4 min (Figure 5.5).  These data strongly 
suggested that the CDSO3 treatment enabled reversal of the functional EE values 
presumably as a result of repair of lung damages. More intriguingly, when CDSO3 was 
pre-mixed with excess Fe2+ (i.e.,10 mM FeSO4) and then administered to the lungs of 
these emphysematous rats, the EE values remained abnormally reduced at 9.5±4.1 
min, which was equivalent to those seen in the saline-treated emphysematous rats. This 
excess Fe2+-induced failure of emphysema reversal was consistent with the mechanism 
of action for CDSO3, as hypothesized in this dissertation research, i.e., Fe2+ chelation-





Figure 5.5:  In vivo reversal of functional treadmill exercise endurance impairment by 
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Figure 5.6: Exercise endurance (EE) values in 5 different treatment groups in a rat 
emphysema model induced by VEGF receptor blockade. Data represent 
mean±standard deviation (SD) from n=3-11; *p<0.05, compared to the healthy 
(negative) control; #p<0.05, compared to the SU5416-induced (positive) control, by 
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 5.3.2 Airspace enlargement and its improvement by CDSO3  
 
 Figure 5.7 shows the representative histological H&E-stained micrographs of the 
left lung lobes taken on day 35 following different treatments.  The mean linear intercept 
(MLI) values for the alveolar airspace size (e.g., enlargement) were determined from 
these micrographs at 25x magnification, as shown in Figure 5.8.  While CDSO3 
treatment alone at 60 µg/kg resulted in the MLI value of 49.5±4.7 µm, which was not 
significantly different from the MLI value of 56.1±6.0 µm for the healthy control rats.  
However, the absence of the alveolar walls was visually apparent in the SU5416-
induced animals (Figure 5.6b) when compared to the healthy control animals (Figure 
5.6a).  As a result, this SU5416-induced airspace enlargement was quantified by a 
significant 46.5 % increase in the MLI value (p<0.05; 56.1±6.0 to 82.2±2.3 µm), as 
shown in Figure 5.7.  In contrast, the 2-week treatment with CDSO3 at 60 µg/kg 
enabled significant recovery in the MLI value by 74.1 % (p<0.05; 82.2±2.3 to 62.9±5.2 
µm).  However, when CDSO3 at 60 µg/kg was pre-mixed with excess Fe2+, and then 
administered to the lungs of these emphysematous rats, the alveolar airspace remained 








a) Healthy control (Saline + Saline)                b) SU5416 + Saline 
     
 
             d) SU5416 + CDSO3 [60 µg/kg] pre-mixed 
c) SU5416 + CDSO3 [60 µg/kg]         with FeSO4 [10 mM] 
     
 
Figure 5.7: Representative histological hematoxylin-eosin (H&E)-stained micrographs 
of the left lung lobes taken on day 35 following SC injection of SU5416 or saline on day 
1 and two-week pulmonary delivery with saline or CDSO3 60 µg/kg ± 10 mM FeSO4.  









Figure 5.8: Mean linear intercept (MLI) values determined from the left lung lobes taken 
on day 35 following different treatment groups in the SU5416-induced rat model of 
emphysema.  + = present; - = absent.  Data represents mean±SD from n=2-11; 
*p<0.05, compared to the healthy control; #p<0.05, compared to the SU5416-induced 
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 5.3.3 Induced alveolar wall destruction and its improvement by CDSO3 
 
 The destructive index (DI) values were determined from the histological H&E-
stained micrographs of the left lung lobes at 25x magnification, and are shown in Figure 
5.9.  Healthy control animals had a DI value of 5.6±2.4 %.  SU5416-induced 
emphysematous animals had a significant 5-fold increase in the DI value (p<0.05; 
5.6±2.4 % to 28.2±7.3 %), demonstrating the severe alveolar wall destruction due to 
SU5416.  Treatment with CDSO3 at 60 µg/kg enabled significant recovery in the DI 
value by 87 % (p<0.05; 28.2±7.3 % to 8.5±1.5 %).  However, when CDSO3 at 60 µg/kg 
was pre-mixed with excess Fe2+ and then administered to the lungs of these 
emphysematous rats, the alveolar structures remained destroyed, comparable to those 













Figure 5.9: In vivo reversal of morphological alveolar destruction by CDSO3, as 
assessed by the destructive index. + = present; - = absent.  Data represent 
mean±standard deviation (SD) from n=3; *p<0.05, compared to vehicle control; #p<0.05, 
compared to the SU5416-induced control; $p<0.05, compared to the SU5416-induced 
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 5.3.4  EE, MLI, and DI correlations 
 
 
 The EE, MLI, and DI values for each animal in the four treatment groups were 
then plotted in Figures 5.10-5.12 to examine their three-way correlations.  Correlations 
were clearly seen in that impaired functional EE was associated with emphysematous 
abnormalities of airspace morphology (MLI and DI), as shown in Figures 5.9 and 5.10, 
respectively.  Lower EE correlated with larger MLI and DI values, suggesting that 
emphysematous rats with impaired exercise endurance exhibited increased alveolar 
airspace enlargement and destruction.  In contrast, as shown in Figure 5.11, alveolar 
destruction/loss (DI) and size enlargement (MLI) in this disease animal model resulted 












Figure 5.10:  Correlation between functional EE and airspace enlargement (MLI).   = 
Healthy control rats,  = SU5416-induced, saline-treated rats,  = SU5416-induced, 
CDSO3-treated rats, and  = SU5416-induced, CDSO3/FeSO4-treated rats   





































Figure 5.11: Correlation between functional exercise endurance (EE) and alveolar 
destruction (DI).  = Healthy control rats,  = SU5416-induced, saline-treated rats,  
= SU5416-induced, CDSO3-treated rats, and  = SU5416-induced, CDSO3/FeSO4-






































Figure 5.12:  Correlation between alveolar airspace enlargement (MLI) and destruction 
(DI).   = Healthy control rats,  = SU5416-induced, saline-treated rats,  = SU5416-





































Destructive index, DI (%) 
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 5.3.5  Lung tissue expression of protein markers 
  
 
 The lung tissue expressions of several proteins were measured using Western 
blot analysis to clarify the mechanism of CDSO3’s reversal of functional and 
morphological impairment, i.e. Fe2+ chelation-dependent hypoxia-inducible factor-1 
(HIF-1) stabilization/stimulation.  Figure 5.13 show that VEGF receptor blockade with 
SU5416 did not significantly change the lung tissue expressions of histone deacetylase 
2 (HDAC2) upstream.  In addition, the lung tissue expressions of HIF-1 in cytoplasmic 
extracts were also unchanged, compared to those of the healthy control animals (Figure 
5.14).  Similarly, treatment with CDSO3 at 60 µg/kg also did not significantly change the 
expressions of HDAC2 or HIF-1, when compared to both the healthy control animals 
and emphysematous animals.  However, CDSO3 at 60 µg/kg administered into the 
lungs significantly increased the expression of VEGF by two-fold, compared to the 
healthy animals (p<0.05).  Instillation of SU5416 significantly reduced the expression of 
VEGF by 52 % (p<0.05), but treatment with CDSO3 at 60 µg/kg in these 
emphysematous animals significantly normalized the expression of VEGF (Figure 5.15).  
Yet, the lung tissue expression of the pro-apoptotic marker, BAX, was unchanged 
across all treatment groups (Figures 5.16, 5.17).  However, SU5416 at 20 mg/kg 
significantly increased the expression of cleaved caspase-3 by almost 1.5-fold, 
compared to the healthy control (p<0.05), and treatment with CDSO3 at 60 µg/kg in 
these emphysematous normalized the expression of cleaved caspase-3 almost to the 
level expressed in healthy control animals.  Furthermore, when CDSO3 at 60 µg/kg was 
premixed with excess Fe2+ and then dosed to the lungs, the expression of cleaved 
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caspase-3 increased significantly by 3.3-fold compared to the expressions of healthy 



































   
 
Figure 5.13.  Rat lung tissue cytoplasmic expression of HDAC, as shown by bands at 
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Figure 5.14.  Rat lung tissue cytoplasmic expression of HIF-1, as shown by bands at 
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Figure 5.15.  Rat lung tissue cytoplasmic expression of VEGF, as shown by bands at 
25 kDa. Data represent mean±SD from n=3-4. *p<0.05, compared to the healthy 
control; #p<0.05, compared to the SU5416-induced animals, by ANOVA and Tukey’s 
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Figure 5.16.  Rat lung tissue cytoplasmic expression of BAX, as shown by bands at 20 
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Figure 5.17.  Rat lung tissue cytoplasmic expression of cleaved caspase-3. Data 
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5.4  DISCUSSION 
 
 The in vivo animal studies of pulmonary emphysema in this chapter have 
successfully demonstrated that pulmonary administration of the 3.3 kDa non-peptidic 
sulfated dehydropolymer of caffeic acid, CDSO3, significantly reversed functional and 
morphological impairments.  The major findings for pulmonary administration of CDSO3 
at 60 µg/kg are as follows: 1) SU5416-induced functional impairment (decreased EE), 
morphological airspace enlargement (increased MLI), and alveolar destruction 
(increased DI) were reversed by 66.5, 74.1, and 87.0 %; 2) the EE, MLI, and DI 
remained impaired when CDSO3 pre-mixed with excess Fe2+; 3) reduced alveolar wall 
destruction is correlated with improvement in functional exercise endurance and 
airspace size; 4) decreased VEGF and increased caspase-3 are normalized. 
 
 5.4.1  CDSO3 reverses functional and morphological impairment 
 
 One SC injection of SU5416 at 20 mg/kg significantly (p<0.05) reduced the EE 
times by 80.8 % (43.3±6.8  8.3±2.8 min), and increased the MLI and DI by 46.5 % 
(56.1±6.0  82.2±2.3 µm) and 5-fold (5.6±2.4  28.2±7.3 %), respectively.  Pulmonary 
administration of CDSO3 at 60 µg/kg for 2 weeks improved the EE, MLI, and DI by 66.5 
% (8.3±2.8 min  31.9±7.4 min), 74.1 % (82.2±2.3  62.9±5.2 µm), and 87.0 % 
(28.2±7.3  8.5±1.5 %).  However, when CDSO3 was pre-mixed with excess Fe2+ (10 
mM FeSO4) and then administered to the lungs of these emphysematous rats, the 
alveolar structures remained destroyed, comparable to those seen in the SU5416-
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induced rats, suggesting a Fe2+ chelation-dependent mechanism.  These findings are 
consistent with CDSO3’s reversal effects in the HSE/CSE and CSE models of 
pulmonary emphysema [Saluja et al., 2014; Sakagami 2016].  
 
 5.4.2  Reduced alveolar wall destruction is correlated with improvement in 
 functional exercise endurance and airspace size  
 
 Correlations were clearly seen in that impaired functional EE was associated with 
emphysematous abnormalities of airspace morphology (MLI and DI), suggesting that 
functional treadmill exercise endurance is a non-invasive test to predict emphysematous 
changes in the lung.  Furthermore, alveolar destruction/loss (DI) resulted in a moderate 
correlation, yet still suggesting that their association in this disease model.  These 
correlations confirm the definition of emphysema, as characterized by the destruction of 
the alveolar walls leading to airspace enlargement and reduced surface area for gas 
exchange, resulting in difficulty breathing. 
 
 5.4.3 CDSO3 increases the expression of VEGF and cleaved caspase-3, but 
 not HDAC, HIF-1, or BAX 
  
 SC SU5416 at 20 mg/kg reduced the expression of VEGF by two-fold and 
increased the expression of cleaved caspase-3 by about 1.5-fold, whereas pulmonary 
treatment with CDSO3 at 60 µg/kg significantly normalized both of these protein.  
However, neither induction with SU5416 at 20 mg/kg nor treatment with CDSO3 were 
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shown to alter the expressions of HDAC2, HIF-1, or the pro-apoptotic marker, BAX.  It 
is notable to mention that the expression of HIF-1 was measured from cytoplasmic 
extracts of lung tissue, which is rapidly degraded by HIF-PHD.  It is the stabilized HIF-
1 that translocates into the nucleus, where it is expected to dimerizes with HIF-1 to 
bind the hypoxia response element (HRE) of target genes to up-regulate VEGF, as 
discussed in Chapter 1.  Therefore, it is necessary to measure the expression of HIF-1 
from nuclear extracts of lung tissue to clarify these findings.  Furthermore, HDAC2 is 
found up-stream of both HIF-1 and VEGF, therefore, its expression may be not be 
altered in by VEGF receptor blockade downstream.   
 
5.5  CONCLUSIONS 
 
 A VEGF receptor blockade apoptotic model of pulmonary emphysema was 
induced in rats by a single orotracheal instillation of SU5416.  CDSO3’s Fe2+ and HIF-
1-dependent reversal of functional and morphological impairment was tested with its 
pulmonary administration at 60 µg/kg three times a week for two weeks after SU5416 
instillation.  The SU5416 instillation successfully caused functional impairment by 
decreasing the EE by 80.8 %, and both morphological airspace enlargement and 
destruction by increasing the MLI and DI values by 46.5 % and 5-fold, respectively, 
compared to those of healthy animals.  CDSO3 at 60 µg/kg significantly reversed these 
functional and morphological impairments by 66.5, 74.1, and 87.0 % (p<0.05).  
However, when CDSO3 at 60 µg/kg was pre-mixed with excess Fe2+, the EE, MLI, and 
DI all remained impaired.  These results clearly suggested that CDSO3 at 60 µg/kg 
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administered to the lungs exerted significant in vivo reversal of functional and 
morphological impairments in an apoptotic model of established emphysema.  However, 
when the lung tissue expressions of several proteins were measured in an attempt to 
clarify this reversal of functional and morphological impairments, the results were mixed 
and inconclusive.  CDSO3 was found to up-regulate/normalize the expression of VEGF 
and cleaved caspase-3, but not HDAC2, HIF-1 or BAX.  Further studies are required 















































 In this dissertation project, the therapeutic potential of sulfated dehydropolymer 
of caffeic acid (CDSO3) was further examined in vitro and in vivo as an oligomer drug 
entity for pulmonary delivery in the treatment of emphysema.  Due to the polydispersity 
and heterogenous nature of its chemical structure, CDSO3 was tested for its batch-to-
batch differences in ferrous (Fe2+) chelation activity as well as its cytoprotective effect 
against apoptotic cell death.  CDSO3’s Fe2+ chelation and HIF-1-dependent in vitro 
cytoprotective activity against different stimuli-induced emphysematous cell death was 
then assessed in three different cell lines involved in the pathogenesis of emphysema.  
It’s ferrous chelating and cytoprotective activities were compared to those of two known 
chelators, DFO and EDTA.  CDSO3’s reversal of functional and morphological 
impairments, as well as stabilization/up-regulation of HIF-1and HIF-regulating proteins 
were then assessed in an in vivo apoptotic model of established emphysema, while 
seeking correlations between exercise endurance, mean linear intercept, and alveolar 
destruction.         
 The in vitro assessment of ferrous (Fe2+) chelating activity employed a ferrozine-
chelation based competitive inhibition assay.  Ferrous (Fe2+) ion when bound by 
ferrozine, resulted in an absorbance at 562 nm, which was decreased in the presence 
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of a competitive chelator molecule, i.e., CDSO3.  The IC50 and HS values were derived 
from non-linear regression curve-fitting.  Two batches of CDSO3, i.e., CDSO3BH and 
CDSO3MT, exhibited comparable Fe2+ chelation activity with IC50 values of 23.3±2.1 (95 
% CI: 18.6, 28.0) and 17.0±1.4 (95% CI: 13.6, 20.5) µM, respectively.  The HS values 
were 1.2±0.1 (95 % CI: 0.9, 1.4) and 1.4±0.2 (95 % CI: 1.0, 1.8), indicating an 
approximately 1:1 stoichiometry for CDSO3 and Fe2+ chelation.  These IC50 and HS 
values were comparable to those of known chelators, DFO and EDTA.  Furthermore, 
CDSO3 did not seem to exhibit ferric (Fe3+) chelation activity in the concentration range 
of 0-50 µM, suggesting its chelation is specific for divalent ions. 
 The in vitro pro-inflammatory TNF-release was measured using an enzyme-
linked immunosorbent assay (ELISA).  1% CSE caused significant ~20-fold increase in 
TNF-a release compared to the vehicle control, and CDSO3 was shown to inhibit this 
CSE-induced TNF- release in a concentration-dependent manner from 1-25 µM, 
reaching significance at 5 µM (~49 % inhibition).  The trypan blue exclusion (TBE) and 
lactate dehydrogenase (LDH) assays were used to assess the in vitro cytoprotective 
activities using rat alveolar macrophage (NR8383), human alveolar epithelial (A549) 
and microvascular lung endothelial (HMVEC-L) cells.  Cell death was induced with CSE, 
H2O2, HSE, TSA, and SU5416.  The HIF-1 inhibitors (CAY10585 or Echinomycin) or 
excess Fe2+ (FeSO4 or FeCl2) or Fe3+ (FeCl3) were added to clarify CDSO3’s Fe2+ 
chelation-dependent HIF-1 up-regulatory mechanism of cytoprotection.  CDSO3 at 10 
µM consistently inhibited these 3-7-fold induced cell death by about 63-154 % in all 
three cell lines, and was shown to be more potent than both the monomer (CA) and the 
un-sulfated oligomer (CD), suggesting that oligomerization and sulfation play key roles 
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in its protection.  Furthermore, the addition of both HIF-1 inhibitors and excess Fe2+, 
regardless of the co-ion, all opposed CDSO3’s cytoprotective activities; excess Fe3+ did 
not have the same effects.  The chelators DFO and EDTA did not exhibit cytoprotection 
despite their equipotent Fe2+ chelation activities, due to their large size and 
hydrophilicity.   
 CDSO3’s Fe2+- and HIF-1-dependent reversal of lung damages in an in vivo rat 
model of apoptotic emphysema induced by VEGF receptor blockade was tested.  
SU5416 induction reduced the EE by 80.8 %, and increased the airspace enlargement 
(MLI) and destruction (DI) by 46.5 and 5-fold, respectively.  Pulmonary delivery of 
CDSO3 at 60 µg/kg significantly improved EE by 66.5 $ to 31.9±7.4 min, and reversed 
MLI and DI impairments by 74.1 and 87.0 %.  However, when CDSO3 was premixed 
with excess Fe2+, the EE, MLI, and DI all remained impaired.  Furthermore, a correlation 
was clearly seen with impaired EE and emphysematous abnormalities of both MLI, 
whereas a moderate correlation was seen between DI and MLI.  SC SU5416 at 20 
mg/kg reduced the expression of VEGF by two-fold and increased the expression of 
cleaved caspase-3 by about 1.5-fold, whereas pulmonary treatment with CDSO3 at 60 
µg/kg significantly normalized both of these protein.  However, neither induction with 
SU5416 at 20 mg/kg nor treatment with CDSO3 were shown to alter the expressions of 
HDAC2, HIF-1, or the pro-apoptotic marker, BAX.  It is notable to mention that the 
expression of HIF-1 was measured from cytoplasmic extracts of lung tissue, which is 
rapidly degraded by HIF-PHD.  It is the stabilized HIF-1 that translocates into the 
nucleus, where it is expected to dimerizes with HIF-1 to bind the hypoxia response 
element (HRE) of target genes to up-regulate VEGF, as discussed in Chapter 1.  
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Therefore, it is necessary to measure the expression of HIF-1 from nuclear extracts of 
lung tissue to clarify these findings.  Furthermore, HDAC2 is found up-stream of both 
HIF-1 and VEGF, therefore, its expression may be not be altered in by VEGF receptor 
blockade downstream.   

















































1.  After 18-24 h incubation, the incubation media (200 µl) was removed from the 
48-well plate and transferred into labeled 1.5 ml microcentrifuge tubes (MCT 
#1)*.   
2. The cells were washed with either 200 µl warm PBS (NR8383 and A549) or 
HEPES (HMVEC-L) twice; a total of 400 µl of PBS or HEPES was recovered into 
the microcentrifuge tubes (MCT #1).     
3. 200 µl of warm trypsin-EDTA was added to each well, and the plate was allowed 
to sit at room temperature for 3-4 minutes to allow the cells to detach.  The cells 
were viewed under the microscope to assure that the majority (>90%) of the cells 
were detached.  An additional 200 µl of incubation media (NR8383 and A549) or 
trypsin neutralizing solution (TNS; HMVEC-L) was added to each well, and 
repeated pipetting was carried out to assure all the cells were detached.  A total 
of 400 µl was transferred into labeled 1.5 ml microcentrifuge tubes (MCT #2). 
4. The tubes (MCT #1 and MCT #2) were centrifuged (Eppendorf Centrifuge 5415 
C) at 12,000 revolutions per minute (RPM) for 3-4 minutes and the supernatant 
was carefully discarded, leaving the cell pellets at the bottom of the tubes.   
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5. The cell pellets from MCT #1 and MCT #2 were re-suspended and combined 
using 100 µl of fresh incubation media. 
6. Trypan blue solution, 4% (Amresco; Solon, OH) was filtered using a 5 ml syringe 
(Becton, Dickinson and Company, BD; Franklin Lakes, NJ) and 0.4-µm filter 
(Drummond Scientific Company; Broomall, PA); 100 µl was added to the re-
suspended cells and allowed to sit for 4-5 minutes. 
7. The tubes were centrifuged at 12,000 RPM for 3-4 minutes; the supernatant was 
carefully removed and discarded.  The cell pellet was re-suspended with 200 µl 
fresh incubation media and plated into a new 48-well plate and allowed to sit for 
at least 2 h to allow the cells to settle. 
8. Using a microscope (Omax, Kent, WA; 100x magnification) and ToupViewX 
(Omax, Kent, WA), at least 8-10 images were taken to allow >300 cells to be 
counted.  Stained blue cells were considered dead and clear/white cells were 
considered live.   
9. % cell death was calculated as:    




10.  *If the LDH assay was performed, MCT #1 was centrifuged at 12,000 for 3-4 
minutes after Step 1, and the supernatant was transferred into newly labeled 
microcentrifuge tubes and stored in -70oC until ready to use for the LDH assay.  
Proceed to Step 2, and combined the cell pellet remaining in MCT #1 with the 
















Day 1:  Place the rat in the treadmill and close the cover.  Turn on the electric shock 
and watch the rat’s movements for 5 minutes.  After 5 minutes, start the treadmill at the 
speed of 2.0 m/min and slowly increase the speed by 1.0-m/m increments when rat 
learns to avoid the electric shock area.  When the speed reaches 5.0 m/min, set the 
timer to 5 minutes.  After 5 minutes, stop the treadmill, and place the rat back into its 
cage.  Repeat the procedure 3 hours later.   
Day 2:  Place the rat in the treadmill and close the cover.  Turn on the electric shock 
and start the treadmill at the speed of 3.0 m/min.  Slowly increase the speed by 1.0-
m/min increments when the rat learns to avoid the electric shock area.    When the 
speed reaches 7.0 m/min, set the timer for 10 minutes.  After 10 minutes, stop the 
treadmill, and place the rat back into its cage.  Repeat the procedure three hours later. 
Day 3:  Place the rat in the treadmill and close the cover.  Turn on the electric shock 
and start the treadmill at the speed of 3.0 m/min.  Slowly increase the speed by 1.0-
m/min increments when the rat learns to avoid the electric shock area.  When the speed 
reaches 10 m/min, set the timer for 10 minutes.  After 10 minutes, stop the treadmill and 
place the rat back into its cage.  Repeat the procedure three hours later.  
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Day 4:  Place the rat in the treadmill and close the cover.  Turn on the electric shock 
and start the treadmill at the speed of 10 m/m.  Set the timer for 15 minutes.  After 15 
minutes, stop the treadmill and place the rat back into its cage.  Repeat the procedure 
three hours later.   
Days 5-10:  Place the rat in the treadmill and close the cover.  Turn on the electric 
shock and start the treadmill at the speed of 10 m/min.  Set the timer for 30 minutes.  
After 30 minutes, stop the treadmill and place the rat back into its cage.  
 
Criteria for a well-trained rat: running on the treadmill without touching the electric shock 
for at least 3 minutes. 
 
Treadmill Running Test 
 
1. Turn on the treadmill and the electric shock. 
2. Raise the height of the treadmill to a 5 degree angle 
3. Place the rat on the treadmill and start at a speed of 10 m/min.  Start the timer 
4. Carefully watch the rat’s running and record how many times it touches the 
shocks in the first 2 minutes. 
5. After 2 minutes, record the time of each shock for 5 shocks total.   
6. When the rat’s running time is over 30 minutes, raise the treadmill angle to 10 
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In vitro anti-cell death activity assessment – Trypan blue exclusion assay 
 
 





Total % Stained 
Dead 
n=1 5 97 102 4.90 
n=2 21 389 410 5.12 
n=3 40 498 538 7.43 
n=4 63 425 488 12.91 
n=5 54 549 603 8.96 
n=6 12 137 149 8.05 
n=7 30 164 194 15.46 
n=8 10 313 323 3.10 
n=9 22 226 248 8.87 










Total % Stained 
Dead 
n=1 14 53 67 20.90 
n=2 12 51 63 19.05 
n=3 16 50 66 24.24 
n=4 16 29 45 35.56 

























Total % Stained 
Dead 
n=1 59 165 224 26.34 
n=2 45 115 160 28.13 
n=3 58 122 180 32.22 
n=4 54 149 203 26.60 










Total % Stained 
Dead 
n=1 57 64 121 47.11 
n=2 37 35 72 51.39 
n=3 57 76 133 42.86 
n=4 22 28 50 44.00 
n=5 64 183 247 25.91 
n=6 82 262 344 23.84 
n=7 95 222 317 29.97 
n=8 63 175 238 26.47 
n=9 62 68 130 47.69 
n=10 50 139 189 26.46 
n=11 77 165 242 31.82 
n=12 74 189 263 28.14 

























Total % Stained 
Dead 
n=1 113 27 140 80.71 
n=2 143 81 224 63.84 
n=3 159 59 218 72.94 
n=4 183 78 261 70.11 










Total % Stained 
Dead 
% Inhibition 
n=1 100 211 311 32.15 12.21 
n=2 69 217 286 24.13 41.77 
n=3 68 256 324 20.99 53.33 
n=4 61 218 279 21.86 50.10 
 Mean 24.78 39.35 
SD 5.09 18.74 
SE 2.54 13.25 
 
 





Total % Stained 
Dead 
% Inhibition 
n=1 65 116 181 35.91 NA 
n=2 46 217 263 17.49 66.20 
n=3 47 221 268 17.54 66.03 
n=4 54 182 236 22.88 46.36 
 Mean 23.46 59.53 
SD 8.68 11.41 


















Total % Stained 
Dead 
% Inhibition 
n=1 44 203 247 17.81 65.03 
n=2 31 247 278 11.15 89.55 
n=3 23 274 297 7.74 102.10 
n=4 31 238 269 11.52 88.19 
n=5 42 222 264 15.91 72.02 
n=6 58 309 367 15.80 72.43 
n=7 37 276 313 11.82 87.08 
n=8 41 385 426 9.62 95.18 
 Mean 12.67 83.95 
SD 3.48 12.81 
SE 1.23 4.53 
 
 





Total % Stained 
Dead 
% Inhibition 
n=1 38 338 376 10.11 93.39 
n=2 54 380 434 12.44 84.79 
n=3 68 286 354 19.21 59.88 
n=4 42 296 338 12.43 84.85 
 Mean 13.55 80.73 
SD 3.93 14.48 
SE 1.97 7.24 
 
 





Total % Stained 
Dead 
% Inhibition 
n=1 18 49 67 26.87 31.69 
n=2 13 38 51 25.49 36.75 
n=3 11 28 39 28.21 26.75 
n=4 7 58 65 10.77 90.95 
 Mean 22.83 46.53 
SD 8.12 29.89 














Total % Stained 
Dead 
n=1 3 159 162 1.85 
n=2 4 141 145 2.76 
n=3 8 176 184 4.35 
n=4 5 143 148 3.38 
n=5 6 94 100 6.00 
n=6 19 759 778 2.44 
n=7 23 652 675 3.41 
n=8 18 777 795 2.26 
n=9 13 720 733 1.77 
n=10 21 707 728 2.88 
n=11 10 678 688 1.45 
n=12 8 432 440 1.82 
n=13 3 231 231 1.30 
n=14 10 411 411 2.43 
n=15 10 307 317 3.15 
n=16 27 630 657 4.11 
n=17 9 369 388 2.32 
n=18 18 725 743 2.42 
n=19 24 732 756 3.17 
n=20 23 643 666 3.45 
n=21 13 770 783 1.66 
n=22 15 693 708 2.12 
n=23 13 605 618 2.10 
n=24 6 387 393 1.53 
n=25 4 369 373 1.07 
n=26 3 291 294 1.02 























Total % Stained 
Dead 
n=1 4 178 182 2.20 
n=2 5 229 234 2.14 
n=3 4 130 134 2.99 
n=4 5 349 354 1.41 
n=5 4 337 341 1.17 
n=6 10 322 332 3.01 










Total % Stained 
Dead 
n=1 52 606 658 7.90 
n=2 54 566 620 8.71 
n=3 41 483 524 7.82 
n=4 64 612 676 9.47 
n=5 63 674 737 8.55 
n=6 71 825 896 7.92 










Total % Stained 
Dead 
% Inhibition 
n=1 18 632 650 2.77 96.20 
n=2 26 652 678 3.83 78.98 
n=3 16 545 561 2.85 94.78 
n=4 16 796 812 1.97 109.86 
n=5 16 786 802 2.00 109.44 
n=6 11 519 530 2.08 108.06 
 Mean 2.58 99.39 
SD 0.73 12.45 













Total % Stained 
Dead 
n=1 52 623 675 7.70 
n=2 41 355 396 10.35 
n=3 30 458 488 6.15 










Total % Stained 
Dead 
n=1 60 458 518 11.58 
n=2 77 523 600 12.83 
n=3 68 580 648 10.49 










Total % Stained 
Dead 
n=1 13 113 126 10.32 
n=2 8 102 110 7.27 
n=3 13 169 182 7.14 
n=4 20 116 136 14.71 





















Total % Stained 
Dead 
% Inhibition 
n=1 11 199 210 5.24 63.20 
n=2 10 221 231 4.33 75.63 
n=3 5 186 191 2.62 99.03 
 Mean 4.06 79.29 
SD 1.33 18.19 
SE 0.77 10.50 
 
 





Total % Stained 
Dead 
% Inhibition 
n=1 5 215 220 2.27 103.79 
n=2 4 187 191 2.09 106.25 
n=3 4 147 151 2.65 98.59 
 Mean 2.34 102.88 
SD 0.28 3.91 
SE 0.16 2.26 
 
 





Total % Stained 
Dead 
n=1 7 169 176 3.98 
n=2 3 108 111 2.70 
n=3 6 169 175 3.43 
n=4 11 94 105 10.48 
n=5 15 187 187 7.43 





















Total % Stained 
Dead 
n=1 8 292 300 2.67 
n=2 8 209 217 3.69 
n=3 13 120 133 9.77 










Total % Stained 
Dead 
n=1 4 232 236 1.69 
n=2 2 190 192 1.04 
n=3 2 119 121 1.65 










Total % Stained 
Dead 
n=1 22 152 174 12.64 
n=2 17 124 141 12.06 
n=3 36 101 137 26.28 










Total % Stained 
Dead 
% Inhibition 
n=1 6 186 192 3.13 96.00 
n=2 5 147 152 3.29 94.86 
n=3 11 172 183 6.01 76.02 
 Mean 4.14 88.96 
SD 1.62 11.22 










Total % Stained 
Dead 
% Inhibition 
n=1 4 206 210 1.90 104.45 
n=2 8 95 103 7.77 63.86 
n=3 2 125 127 1.57 106.73 
 Mean 3.75 91.68 
SD 3.48 24.12 
SE 2.01 13.92 
 
 





Total % Stained 
Dead 
n=1 41 472 513 7.99 
n=2 41 552 593 6.91 
n=3 46 601 647 7.11 










Total % Stained 
Dead 
n=1 39 790 829 4.70 
n=2 35 717 732 4.65 
n=3 36 715 751 4.79 










Total % Stained 
Dead 
n=1 36 795 831 4.33 
n=2 22 710 732 3.01 
n=3 22 539 561 3.92 












Total % Stained 
Dead 
n=1 22 219 241 9.13 
n=2 42 485 485 8.66 
n=3 24 276 252 8.70 
n=4 27 358 385 7.01 
n=5 44 430 474 9.28 
n=6 34 303 337 10.09 
n=7 46 439 485 9.48 
n=8 45 414 459 9.80 
n=9 57 580 580 8.95 










Total % Stained 
Dead 
n=1 24 360 384 6.25 
n=2 13 364 387 5.94 
n=3 16 385 401 3.99 










Total % Stained 
Dead 
% Inhibition 
n=1 19 370 389 4.88 63.38 
n=2 19 455 474 4.01 76.84 
n=3 16 392 408 3.92 78.17 
n=4 13 355 368 3.53 84.14 
n=5 30 475 505 5.94 47.16 
n=6 24 348 372 6.45 39.32 
n=7 11 396 407 2.70 96.89 
n=8 13 337 350 3.71 81.35 
n=9 23 379 402 5.72 50.53 
 Mean 4.54 68.64 
SD 1.27 19.48 









Total % Stained 
Dead 
n=1 31 351 382 8.12 
n=2 24 256 280 8.57 
n=3 24 285 309 7.77 
n=4 46 421 467 9.85 
n=5 41 380 421 9.74 
n=6 36 341 377 9.55 










Total % Stained 
Dead 
n=1 28 226 254 11.02 
n=2 31 365 396 7.83 
n=3 22 242 264 8.33 
n=4 29 200 229 12.66 
n=5 35 222 257 13.62 
n=6 32 273 305 10.49 










Total % Stained 
Dead 
n=1 23 230 253 9.09 
n=2 19 233 252 7.54 
n=3 23 242 265 8.68 
n=4 32 240 272 11.76 
n=5 31 304 335 9.25 
n=6 35 210 245 14.29 














Total % Stained 
Dead 
n=1 54 735 789 6.84 
n=2 52 609 661 7.87 
n=3 45 717 762 5.91 










Total % Stained 
Dead 
n=1 40 619 659 6.07 
n=2 60 586 646 9.29 
n=3 34 612 646 5.26 










Total % Stained 
Dead 
n=1 64 653 717 8.93 
n=2 65 556 621 10.47 
n=3 60 552 612 9.80 
n=4 35 275 310 11.29 
n=5 34 336 370 9.19 
n=6 52 284 336 15.48 










Total % Stained 
Dead 
n=1 111 568 679 16.35 
n=2 79 540 619 12.76 
n=3 67 598 665 10.08 









Total % Stained 
Dead 
n=1 128 480 608 21.05 
n=2 144 517 661 21.79 
n=3 165 439 604 27.32 










Total % Stained 
Dead 
% Inhibition 
n=1 18 403 421 4.28 78.76 
n=2 18 339 357 5.04 69.59 
n=3 15 282 297 5.05 69.49 
 Mean 4.79 72.61 
SD 0.44 5.32 
SE 0.26 3.07 
 
 





Total % Stained 
Dead 
n=1 5 370 375 1.33 
n=2 2 292 294 0.68 
n=3 14 302 316 4.43 










Total % Stained 
Dead 
n=1 44 321 365 12.05 
n=2 53 334 387 13.70 
n=3 28 295 323 8.67 












Total % Stained 
Dead 
n=1 12 401 413 2.91 
n=2 6 347 353 1.70 
n=3 3 305 308 0.97 










Total % Stained 
Dead 
n=1 51 375 426 11.97 
n=2 50 292 342 14.62 
n=3 36 310 346 10.40 



































Total % Stained 
Dead 
n=1 18 416 434 4.15 
n=2 13 303 316 4.11 
n=3 9 252 261 3.45 
n=4 24 360 384 6.25 
n=5 28 484 512 5.47 
n=6 29 404 433 6.70 
n=7 28 451 479 5.85 
n=8 34 453 487 6.98 
n=9 28 399 427 6.56 
n=10 15 289 304 4.93 
n=11 12 265 277 4.33 
n=12 21 299 320 6.56 
n=13    2.44 
n=14    3.41 
n=15    2.26 










Total % Stained 
Dead 
n=1 12 274 286 4.20 
n=2 15 313 328 4.57 
n=3 10 254 264 3.79 
n=4 36 467 503 7.16 
n=5 20 397 417 4.80 
n=6 19 254 273 6.96 
n=7 11 293 304 3.62 
n=8 21 306 327 6.42 
n=9 15 289 304 4.93 

















Total % Stained 
Dead 
n=1    7.90 
n=2    8.71 
n=3    7.82 










Total % Stained 
Dead 
% Inhibition 
n=1    2.77 165.6 
n=2    3.83 132.89 
n=3    2.85 163.10 
 Mean 3.15 153.9 
SD 0.59 18.20 
SE 0.34 10.51 
 
 





Total % Stained 
Dead 
n=1 38 207 245 15.51 
n=2 64 209 273 23.44 
n=3 78 218 296 26.35 
n=4 113 270 383 29.50 
n=5 152 397 549 27.69 
n=6 179 455 634 28.23 
























n=1 24 221 245 9.80 76.24 
n=2 18 197 215 8.37 83.33 
n=3 28 186 214 13.08 59.89 
n=4 78 489 567 13.76 56.54 
n=5 85 498 583 14.58 52.45 
n=6 81 480 561 14.44 53.15 
 Mean 12.34 63.60 
SD 2.39 13.01 
SE 0.97 5.31 
 
 





Total % Stained 
Dead 
n=1 143 298 441 32.43 
n=2 102 304 406 25.12 
n=3 56 149 205 27.32 










Total % Stained 
Dead 
n=1 116 287 403 28.78 
n=2 119 262 381 31.23 
n=3 91 184 275 33.09 










Total % Stained 
Dead 
n=1 77 272 349 22.06 
n=2 77 289 366 21.04 
n=3 74 328 402 18.41 













n=1 32 295 327 9.78 73.23 
n=2 34 378 412 8.25 83.71 
n=3 21 349 370 5.68 101.32 
 Mean 12.34 68.09 
SD 2.39 14.09 
SE 0.97 8.19 
 
 





Total % Stained 
Dead 
n=1 46 257 303 15.2 
n=2 45 254 299 15.1 
n=3 47 318 365 12.9 










Total % Stained 
Dead 
n=1 52 248 300 17.3 
n=2 50 207 257 19.5 
n=3 45 280 325 13.8 










Total % Stained 
Dead 
n=1 12 289 301 4.0 
n=2 28 261 289 9.7 
n=3 26 310 336 7.7 












Total % Stained 
Dead 
n=1 166 369 535 31.03 
n=2 138 314 452 30.53 
n=3 125 347 472 26.48 















n=1 67 311 378 17.72 49.52 
n=2 73 317 390 18.72 45.26 
n=3 57 302 359 15.88 57.36 
 Mean 17.44 50.71 
SD 1.44 6.14 
SE 0.83 3.54 
 
 





Total % Stained 
Dead 
n=1 100 284 384 26.04 
n=2 101 238 339 29.79 
n=3 95 267 362 26.24 










Total % Stained 
Dead 
n=1 119 261 380 31.3 
n=2 128 204 332 38.6 
n=3 119 246 365 32.6 






CDSO3BH - Ferrozine chelating assay 
CDSO3 Abs Fraction % 
[µM] [M] #1 #2 #3 mean SD mean SD mean SD 
0.0 0.0E+00 0.606 0.696 0.579 0.627 0.061 1.000 0.098 100.00 9.77 
0.1 1.0E-07 0.634 0.606 0.573 0.604 0.031 0.964 0.049 96.38 4.87 
0.5 5.0E-07 0.550 0.635 0.609 0.598 0.044 0.954 0.069 95.37 6.95 
1.0 1.0E-06 0.461 0.610 0.564 0.545 0.076 0.869 0.122 86.92 12.17 
5.0 5.0E-06 0.554 0.539 0.530 0.541 0.012 0.863 0.019 86.28 1.93 
10.0 1.0E-05 0.446 0.448 0.476 0.457 0.017 0.728 0.027 72.83 2.68 
25.0 2.5E-05 0.373 0.281 0.344 0.333 0.047 0.531 0.075 53.06 7.50 
50.0 5.0E-05 0.236 0.135 0.118 0.163 0.064 0.260 0.102 26.00 10.17 
100.0 1.0E-04 0.111 0.058 0.029 0.066 0.042 0.105 0.066 10.53 6.63 
200.0 2.0E-04 0.062 0.070 0.058 0.063 0.006 0.101 0.010 10.10 0.97 
250.0 2.5E-04 0.044 0.042 0.046 0.044 0.002 0.070 0.003 7.02 0.32 
500.0 5.0E-04 0.015 0.012 0.016 0.014 0.002 0.023 0.003 2.29 0.33 
1000.0 1.0E-03 -0.001 0.015 0.008 0.007 0.008 0.012 0.013 1.17 1.28 
 164 
CDSO3MT – Ferrozine chelating assay 
CDSO3 Abs Fraction % 
[µM] [M] #1 #2 #3 mean SD mean SD mean SD 
0.0 0.0E+00 0.385 0.381 0.370 0.379 0.008 1.000 0.021 100.00 2.12 
0.1 1.0E-07 0.376 0.373 0.374 0.374 0.002 0.989 0.004 98.86 0.42 
0.5 5.0E-07 0.375 0.366 0.319 0.353 0.030 0.933 0.082 93.31 8.22 
1.0 1.0E-06 0.366 0.366 0.355 0.362 0.006 0.957 0.017 95.69 1.74 
5.0 5.0E-06 0.299 0.329 0.297 0.308 0.018 0.814 0.049 81.43 4.90 
10.0 1.0E-05 0.262 0.266 0.242 0.257 0.013 0.678 0.035 67.78 3.51 
20.0 2.0E-05 0.220 0.191 0.161 0.191 0.030 0.504 0.081 50.35 8.06 
50.0 5.0E-05 0.048 0.055 0.040 0.048 0.008 0.126 0.021 12.59 2.05 
100.0 1.0E-04 0.027 0.019 0.021 0.022 0.004 0.059 0.011 5.90 1.14 
            
EDTA – Ferrozine chelating assay 
EDTA Abs Fraction % 
[µM] [M] #1 #2 #3 mean SD mean SD mean SD 
0.0 0.0E+0 0.534 0.524 0.571 0.543 0.025 1.000 0.046 100.00 4.56 
0.1 1.0E-07 0.613 0.591 0.594 0.599 0.012 1.104 0.022 110.37 2.20 
0.5 5.0E-07 0.513       ---- 0.553 0.533 0.028 0.982 0.052 98.16 5.21 
1.0 1.0E-06 0.598 0.562 0.571 0.577 0.019 1.063 0.035 106.26 3.45 
2.0 2.0E-06 0.571 0.534 0.569 0.558 0.021 1.028 0.038 102.76 3.83 
5.0 5.0E-06 0.533 0.429 0.371 0.444 0.082 0.818 0.151 81.83 15.12 
10.0 1.0E-05 0.435 0.371 0.391 0.399 0.033 0.735 0.060 73.48 6.03 
20.0 2.0E-05 0.336 0.244 0.226 0.269 0.059 0.495 0.109 49.48 10.87 
50.0 5.0E-05 0.101 0.144       ---- 0.123 0.030 0.226 0.056 22.56 5.60 
100.0 1.0E-04 0.147       ---- 0.161 0.154 0.010 0.284 0.018 28.36 1.82 
200.0 2.0E-04 0.118       ---- 0.115 0.117 0.002 0.215 0.004 21.45 0.39 





Healthy control CDSO3 [60 µg/kg] SU5416 [20 mgkg] 
+ Saline + CDSO3 [60 µg/kg] + CDSO3 [60 µg/kg] pre-
mixed with FeSO4 [10 mM] 
1 TR175 TR76 TR26 TR110 
2 TR176 TR77 TR101 TR111 
3  TR102 TR114 TR112 
4  TR103 TR163 TR113 
5  TR181 TR167  
6  TR193 TR168  
7  TR195 TR171  
8  TR206 TR172  
9  TR207 TR194  
10  TR208 TR209  
11   TR210  
TR203   TR211  
TR204     









In vivo exercise endurance (EE) data 
 
Healthy (negative) control 
PBS + PBS 


















Healthy CDSO3 control 





TR175 42.75 40.98 
TR176 45.73 42.28 
Mean 44.24 41.63 






















Pre-induction Post-treatment Post-treatment 
TR76 - 13.9 13.6 
TR77 - 9.85 14.55 
TR102 - 9.97 9.27 
TR103 - 4.29 5.06 
TR181 - 5.01 2.82 
TR193 - 8.70 8.59 
TR195 - 8.85 6.74 
TR206 58.50 7.68 9.47 
TR207 40.30 8.92 9.44 
TR208 30.12 5.65 6.01 
Mean 42.97 8.28 8.56 
SD 14.38 2.82 3.63 
 
 




Pre-induction Post-induction Post-treatment 
TR26 - 12.78 41.82 
TR101 - 10.40 34.62 
TR114 - 15.25 32.12 
TR163 - 16.26 33.61 
TR167 - 12.80 40.21 
TR168 - 8.11 34.83 
TR171 - 11.72 32.74 
TR172 - 12.01 34.74 
TR194 - 13.19 35.80 
TR209 37.90 10.58 22.93 
TR210 54.08 8.02 19.74 
TR211 33.20 7.97 19.19 
Mean 41.73 11.59 31.87 



















TR110 5.52 15.53 
TR111 6.70 6.09 
TR112 9.15 8.54 
TR113 8.68 7.90 
Mean 7.51 9.51 




In vivo mean linear intercept (MLI) data 
Left lung section 
 
Healthy (negative) control 
PBS + PBS 
















Healthy CDSO3 control 
PBS + CDSO3 












SU5416 + PBS 









SU5416 + CDSO3 



































In vivo destructive index (DI) data 
Left lung section 
 
Healthy (negative) control 
PBS + PBS 
Animal Destroyed Normal Total DI (%) 
1 156 2966 3122 5.00 
2 165 1845 2010 3.49 
3 106 2932 3038 8.21 
   Mean 5.56 




SU5416 + PBS 
Animal Destroyed Normal Total DI (%) 
TR77 404 1624 2028 19.92 
TR102 680 1330 2010 33.83 
TR103 612 1376 1988 30.78 
   Mean 28.18 
   SD 7.31 
 
 
SU5416 + CDSO3 
Animal Destroyed Normal Total DI (%) 
TR26 305 2695 3000 10.17 
TR101 241 2764 3005 8.02 
TR171 144 1860 2004 7.19 
   Mean 8.46 
   SD 1.54 
 
 
SU5416 + CDSO3 pre-mixed with FeSO4 
Animal Destroyed Normal Total DI (%) 
TR110 447 1640 2087 21.42 
TR111 434 1591 2025 21.43 
TR112 539 1496 2035 26.49 
   Mean 23.11 
   SD 2.92 
 
 
